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ABSTRACT
In 2007, AIDS caused an estimated 2.1 millions deaths worldwide; about 70% in sub-Saharan 
Africa. HIV preferentially targets activated CD4 T cells, expressing the major HIV receptor 
CD4, as well as the major chemokine coreceptors CCR5 and CXCR4. These coreceptors play 
a prominent role during HIV cell entrance phase, HIV transmission and also disease 
progression. They have been found to be differentially expressed by CD4 T cell subsets. 
Tuberculosis coinfection may enhance immune activation in vivo thus accelerating HIV 
disease progression and has become a major challenge in the control of TB in Africa. 
Introduction of HAART has reduced disease progression to AIDS, as well as risk of further 
morbidity and mortality. HAART results in a rapid decline of viral load and an initial increase 
of peripheral CD4 count, however little is known on the effect of HAART in regulation of 
coreceptor expression, immune activation status and CD4 T cell subset distribution in HIV 
infection and HIV/TB coinfection. 
This study is a cross-sectional analysis of coreceptor expression, immune activation status and 
CD4 T cell subpopulation distribution in South African HIV and HIV/TB coinfected patients 
before and after ARV. A total of 137 South African individuals were investigated, comprising 
15 healthy normal donors (healthy subgroup), 10 patients with active pulmonary tuberculosis 
(PTB subgroup), 33 HIV-1 positive patients without active PTB (HIV subgroup), 23 positive 
patients with active PTB (HIV/PTB subgroup), 36 HIV-1 positive patients on ARV (HIV on 
ARV subgroup) and 20 HIV-1 positive patients with active PTB on ARV (HIV/PTB on ARV 
subgroup).
CD4 absolute count and plasma viral load were determined for all donors. Freshly isolated 
PBMC were classified by flow cytometry into the following CD4+ T lymphocyte subsets: 
naïve (CD45+, CD27+), effector memory (CD45-, CD27-), central memory (CD45-, CD27+), 
and effector (CD45+, CD27-). Coreceptor expression and activation status was assessed by 
CCR5, CXCR4 and CD38 expression on CD4 T cell subsets. 
HIV, TB and HIV/TB coinfection was associated with a decrease in percentage CCR5+ T 
cells as compared to healthy controls, with the HIV/TB group showing the most extensive 
decrease. In treatment naive patients, CD4 T cells showed elevated surface expression of 
CCR5 and CD38 as determined by mean fluorescence intensity in HIV/TB co-infection 
compared to HIV infection alone. The percentage of antigen-experienced cells was higher in 
vthe HIV/TB co-infected group compared to the HIV group. The percentage of naïve T cells 
was decreased in both the HIV infected and the HIV/TB co-infected groups compared to 
healthy controls. HIV patients with more than 6 months of ARV showed decreased CCR5 and 
CD38 surface level expression in the HIV and the HIV/ TB co-infected subgroups. An 
increased percentage of naïve T cells was observed in the HIV infected subgroup, but not in 
the HIV/TB subgroup, similarly, a decreased percentage of antigen-experienced cells was 
observed in the HIV subgroup, but not in the HIV/TB co-infected subgroup. A positive 
correlation was found between CCR5 and CD38 expression, and CXCR4 and CD38 
expression (Spearman coefficient of correlation respectively: r=0.59, p<0.001 and r=0.55, 
p<0.001). Furthermore we found plasma viral load positively associated with CD38 
expression (r=0.31, p<0.001) and percentage activated CCR5+ expressing CD4 T cells 
positively related to viral load (r=0.31, p<0.001). Percentage naïve CD4 T cells was positively 
associated with CD4 count (r=0.60, p<0.001) and negatively correlated to viral load (r=-0.42, 
p<0.001).
These results indicate that TB coinfection exacerbates certain aspects of dysregulation of CD4 
T cell homeostasis and activation caused by HIV infection. In addition, ARV-associated 
decrease in coreceptor expression, immune activation status and a normalisation of CD4 T 
cell subset distribution was observed in HIV infected individuals, but not in HIV/TB co-
infection. Despite viral suppression after ARV treatment, the decline in the immune activation 
marker CD38 and coreceptor CCR5 expression, increase in percentage naïve CD4 T cells and 
decrease of antigen-experienced cells did not reach the levels displayed in the healthy control 
group. This may indicate that ongoing (albeit reduced) T cell immune activation may occur in 
the presence of ARV. Further longitudinal studies are needed to closely monitor immune 
activation during ARV treatment.
This study highlighted an association of TB disease with immune activation in HIV infection,
the importance of T-cell activation in HIV pathogenesis and its impact on ARV treatment. 
Further studies are needed to identify causative factors that may lead to a persistent immune 
activation status during ARV treatment, and how TB coinfection confounds normal responses 
to ARV.
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OPSOMMING
In 2007 was ongeveer 2.1 miljoen sterftes wêreldwyd veroorsaak deur VIGS; ongeveer 70% 
in Sub-Sahara Afrika. CD4 T selle is die hoof teiken van MIV, aangesien dit die primêre CD4 
reseptor, sowel as een of beide van die vernaamste chemokien koreseptore CCR5 en CXCR4 
vrystel. Hierdie koreseptore speel ‘n prominente rol wanneer die MIV die sel binnedring, 
asook tydens MIV oordrag en verloop van die siekte. Dit word ook deur verskillende fraksies 
van CD4 T selle vrygestel. Gelyktydige TB infeksie mag immuunaktivering in vivo verhoog 
en dus die siekeproses versnel. MIV het ‘n groot uitdaging geword in die beheer van TB in 
Afrika. Bekendstelling van HAART het die ontwikkeling van VIGS vertraag, asook die risiko 
van verdere morbiditeit en mortaliteit. HAART veroorsaak ‘n vinnige afname in virale lading 
‘n toename in CD4 telling, hoewel die spesifieke invloed van HAART op die regulering van 
koreseptor vrystelling, immuunaktivering en verspreiding van CD4 fraksies in MIV en 
MIV/TB infeksies nog onduidelik is.
Hierdie studie het gepoog om koreseptor vrystelling, immuunaktiveringstatus en die 
verspreiding van CD4 subpopulasies in pasiënte met MIV en MIV/TB voor en na ARV 
behandeling te ondersoek. ‘n Totaal van 137 Suid-Afrikaanse individue is ondersoek en die 
studiegroep het bestaan uit 15 normale persone (gesonde subgroep), 10 pasiënte met aktiewe 
pulmonale TB (PTB subgroup), 33 MIV positiewe pasiënte sonder PTB (MIV subgroep), 23 
MIV positiewe pasiënte met aktiewe PTB (MIV/PTB subgroep), 36 MIV positiewe pasiënte 
op ARV (MIV op ARV subgroep) en 20 MIV positiewe pasiënte met aktiewe PTB op ARV 
(MIV/PTB op ARV subgroep).
Absolute CD4 telling en virale ladings was bepaal vir alle deelnemers.  Vars geïsoleerde 
perifere bloed mononukleêre selle is geklassifiseer deur middel van vloeisitometrie as die 
volgende CD4 T limfosiet subgroepe: naïewe selle (CD45+, CD27+), effektor geheueselle 
(CD45-, CD27-), sentrale geheueselle (CD45-, CD27+), en effektor selle (CD45+, CD27-). 
Koreseptor vrystelling en aktivering was beoordeel volgens CCR5, CXCR4 en CD38 
vrystelling op CD4 T sel subgroepe. 
HIV, TB en MIV/TB ko-infeksie is geassosieer met ‘n afname in die persentasie CCR5+ T 
selle, vergeleke met gesonde kontroles, waar die MIV/TB subgroep die grootste afname 
getoon het. In onbehandelde pasiënte het die CD4 T selle verhoogde vrystelling van CCR5 en 
CD38 op die oppervlakte getoon en dit is bevestig deur die gemiddelde fluoresserende 
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intensiteit in die MIV/TB subgroep vergeleke met die subgroep met slegs MIV. Die MIV/TB 
subgroep het verder ook ‘n verhoogde persentasie totale geheue T selle getoon vergeleke met 
die MIV subgroep.  Die persentasie naïewe T selle was egter verlaag in beide die MIV en 
MIV/TB subgroepe vergeleke met normale kontroles.  MIV pasiënte wat langer as 6 maande 
op ARV behandeling was in beide die MIV en MIV/TB subgroepe, het ‘n verlaagde 
vrystelling van CCR5 en CD38 op die oppervlakte van die CD4 selle getoon.  ‘n Verhoogde 
persentasie naïewe T selle het in die MIV subgroep voorgekom, maar nie in die MIV/TB 
subgroup nie.  ‘n Soortgelyke tendens is gevind waar die persentasie totale geheueselle 
verlaag was in die MIV subgroep, maar nie in die MIV/TB subgroep nie.  ‘n Positiewe 
korrelasie is gevind tussen CCR5 en CD38 vrystelling, asook CXCR4 en CD38 vrystelling 
(Spearman korrelasie koëffisiënt: r=0.59, p<0.001 en r=0.55, p<0.001 onderskeidelik). Verder 
het die plasma virale lading ‘n positiewe assosiasie getoon met CD38 vrystelling (r=0.31, 
p<0.001) en die persentasie geaktiveerde CCR5+ vrystellende CD4 T selle met virale lading 
(r=0.31, p<0.001). Die persentasie naïewe CD4 T selle het ‘n positiewe assosiasie getoon met 
CD4 telling (r=0.60, p<0.001) en ‘n negatiewe korrelasie met virale lading (r=-0.42, 
p<0.001).
Volgens hierdie resultate vererger TB ko-infeksie sekere aspekte van die disregulasie van 
CD4 T selhomeostase en aktivering as gevolg van MIV infeksie.  Verder kon ‘n ARV-
geassosieerde afname in koreseptor vrystelling, immuunaktivering en normalisering van CD4 
T sel fraksies bespeur word in die MIV subgroep, maar nie in die MIV/TB subgroep nie.  Ten 
spyte van virale onderdrukking veroorsaak deur ARV behandeling, het die afname in die 
immuunmerker CD38 en koreseptor CCR5, toename in die persentasie naïewe CD4 selle en 
afname in totale geheue CD4 T selle nie die vlakke van die normale kontrolegroep bereik nie.  
Dit is moontlik dat volgehoue verlaagde T sel immuunaktivering nog steeds mag plaasvind in 
die teenwoordigheid van ARV.  Verdere longitudinale studies is nodig om immuunaktivering 
tydens ARV behandeling te monitor.
Hierdie studie het die belangrikheid van T sel aktivering in MIV patogenese en dit impak 
daarvan op ARV behandeling beklemtoon.  Verdere studies is nodig om moontlike oorsake of 
bydraende faktore te identifiseer wat tot volgehoue immuunaktivering tydens ARV 
behandeling kan lei, asook tot mate waartoe TB ko-infeksie kan inmeng met die normale 
werking van ARV behandeling.
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1CHAPTER 1:  INTRODUCTION
The first reports of what became known as Acquired Immune Deficiency Syndrome (AIDS) 
were published in May 1981. They described unusual cases of Pneumocystis pneumonia and 
Kaposi’s sarcoma among injecting drug users and homosexual men in the USA (CDC, 1981). 
Two years later, HIV-1 (Human immunodeficiency virus type 1) was defined as the primary 
cause of AIDS (Barre-Sinoussi et al., 1983). A second similar, but antigenically distinct 
retrovirus named HIV-2 (Human immunodeficiency virus type 2), was isolated from patients 
with AIDS in West Africa in 1986 (Clavel et al., 1986). HIV-1 is now distributed worldwide, 
while HIV-2 remains predominantly localised in West Africa.
The earliest known HIV positive serum sample was collected in Leopoldville in 1959 (now 
Kinshasa, Democratic Republic of Congo) (Zhu et al., 1998; Nahmias et al., 1986; Yusim et
al., 2001). Korber et al. (2000) have analysed envelope gene sequences of HIV-1 isolates 
from more than 150 individuals and estimated the common ancestor of the M group at 1931, 
with a confidence interval of 1915-1941. 
In 2007, 26 years after initial description of HIV/AIDS, an estimated 33.2 million people 
were living with HIV-1 worldwide (Figure 1.1), 2.5 million new HIV infections were reported 
and 2.1 millions deaths were attributed to AIDS. Every day over 6 800 persons become 
infected with HIV and over 5 700 persons die from AIDS (UNAIDS/WHO, 2008). There is 
no region of the world untouched by this pandemic (Incardi and Williams, 2005).
Sub-Saharan Africa remains the most affected region in the global AIDS epidemic. More than 
two thirds (68%) of all people who are HIV-positive live in this region where more than three 
quarters (76%) of all AIDS deaths in 2007 also occurred (UNAIDS/WHO, 2008). South 
African antenatal clinic surveillance data have indicated prevalence rates among pregnant 
women of 30.2% in 2005, 29.1% in 2006 and 28% in 2007 (National Department of Health, 
South Africa, 2008). There is as yet no effective AIDS vaccine. Development of a safe, 
effective, easily administered and affordable HIV vaccine is urgently needed, but remains a 
major challenge.
Introduction of HAART (highly active antiretroviral [ARV] therapy) has reduced disease 
progression to AIDS and transformed HIV infection from a fatal condition to a manageable, 
chronic illness (Incardi and Williams, 2005; Girard et al., 2006; Berrey et al., 2001). Use of 
HAART results in a rapid decline of viral load, an initial immune reconstitution, as well as a 
2decrease in risk of further morbidity and mortality (Giovannetti et al., 1999; Palella et al., 
1998; Murphy et al., 2001). The most common reasons for ARV failure are variability of HIV 
strains, latency during the replication cycle, emergence of drug resistance, as well as non-
adherence to HIV treatment (Del Rio, 2006).
The CD4 molecule is the primary cellular receptor for HIV (Dalgleish et al., 1984). The 
chemokine receptors CCR5 (also termed CD195) and CXCR4 (also termed CD184 or Fusin) 
are the major coreceptors involved in HIV infection and have also been implicated in disease 
progression (Princen and Schols, 2005).That is why in this study, the two majors coreceptors, 
CCR5 and CXCR4, critical in HIV infection have been investigated. The coreceptors are 
differentially expressed on T cell subsets (Zhang et al., 1998). While reports on North 
American and European cohorts demonstrated increasing Subtype B usage of CXCR4 as 
disease becomes more severe, studies from India, Ethiopia, Malawi and South Africa have 
however reported that Subtype C almost exclusively uses CCR5, with CXCR4 usage being 
rarely observed (Cilliers et al., 2003). Fraziano et al. (1999) reported increased CCR5 
expression in active tuberculosis (TB) infection. Similarly, Morris et al. (2001) found CCR5 
to be the major coreceptor used by HIV-1 subtype C isolates from patients with active 
tuberculosis. More studies of normal CCR5 expression on CD4+ T cells in the South African 
population where HIV-1 subtype C predominates is needed to understand the role of 
coreceptor expression in HIV pathogenesis in this region (Morris et al., 2001).
T cell activation is known to be critical for productive viral infection, as activated T cells are 
the main targets for HIV (Siliciano and Siliciano, 2000). However, little is known on the 
effective role of HAART in regulation of coreceptor expression, immune activation status and 
T cell subset distribution in HIV infection and HIV/TB coinfection in South Africa.
Concurrent infections, such as tuberculosis, particularly in Africa, may lead to various degrees 
of immune activation in vivo, thus enhancing HIV infection and accelerating disease 
progression (Bentwich et al., 2000; Morris et al., 2003), eventually resulting in failed ARV 
therapy (Burman and Jones, 2001). HIV infection has become a major challenge in the control 
of TB, mainly due to complications involved in optimal management of concurrent treatment. 
Previous studies have found that HAART lead to CCR5 normalization, whereas CXCR4 
expression did not change significantly (Pierdominici et al., 2002; Giovannetti et al., 2001; 
Nicholson et al., 2001). Such modification in the expression of host determinants of viral 
tropism may play a role in the emergence of virus variants when HAART failure occurs 
3(Giovannetti et al., 1999; Miller et al., 2002; Johnston et al., 2003; Brito et al., 2007). 
Differences in target cells, tissue distribution and replication characteristics between R5- and 
X4-tropic viruses may affect the impact of HAART on HIV coreceptor expression (Skrabal et 
al., 2003; Zhang et al., 2006). R5-tropic viruses are viruses using HIV coreceptor CCR5 and 
X4-tropic viruses using HIV coreceptor CXCR4 (Berger et al, 1999; Princen and Schols, 
2005).  
The continued upregulated CXCR4 expression after HAART (Manetti et al., 2000) may also 
reflect the relative change at the T-cell subset level (Naïve versus memory T cells). 
The current research project was a cross-sectional study performed to assess the effect of 
ARV on coreceptor expression, activation status and CD4 T cell subset distribution in 
peripheral blood of adult South African HIV and HIV/ TB co-infected patients. 
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Figure 1.1. Estimated number of people living with HIV worldwide in 2007 (from 
http//www.unaids.org/2007). This map shows HIV infection predominantly affecting 
the Sub-Saharan region of Africa (UNAIDS/WHO, 2008).
4CHAPTER 2:  LITERATURE REVIEW
2.1. HIV:  Structure and Replication
HIV-1 belongs to the lentivirinae subfamily of Retroviridae. They are enveloped RNA viruses 
producing slow, progressive infection. All lentivirinae, including HIV-1, have a latency 
period before the manifestation of clinical illness (Luciw, 1996).
The HIV-1 virion, which measures 100 nm in diameter, comprises a core composed of 
nucleoproteins complexed to two genomic ribonucleic (RNA) molecules, a capsid which 
encapsulates the ribonucleoprotein particle, a matrix, which surrounds this capsid, and an 
envelope that in turn surrounds the matrix. HIV-1 has nine genes in its 9 kB RNA, including 3 
structural genes (gag, pol and env) (Figure 2.1) and 6 regulatory genes (tat, rev, nef, vif, vpr 
and vpu).
Figure 2.1. Structure of an HIV virion particle. This figure depicts the genomic RNA and viral 
components coded by the 3 structural genes (pol, gag and env):  Env (with gp120 and 
gp41); Gag (with MA, matrix protein or p17, CA, capsid protein or p24 and NC, 
nucleocapsid protein or p7); Pol (with RT, reverse transcriptase) (Sierra, 2005)
The HIV replication cycle (Figure 2.2) consists of 3 main steps: (i) HIV entry into the cell, (ii) 
replication and transcription, and (iii) assembly and release. HIV entry into the host cell 
begins through interaction of the envelope glycoprotein complex, gp120, with both CD4 and a 
chemokine receptor (CCR5 or CXCR4) (Dalgleish et al., 1984; Dimitrov et al., 1998; Feng et 
al., 1996). This interaction allows the N-terminal fusion peptide, gp41, to penetrate the cell 
5membrane (Chan and Kim, 1998; Liu, 2007). This process sees the membranes of the virus 
and the host cell fusing, which allows for subsequent entry of the capsid. Once the viral 
capsid enters the cell, viral RNA is released from the capsid, a process involving proper 
uncoating of the core that is critical for the virus to undergo reverse transcription (Dismuke 
and Aiken, 2006; Nisole and Saib, 2004). Virus-associated reverse transcriptase then converts 
HIV single-stranded RNA into complementary DNA. The nascent complementary viral DNA 
is then transported into the cell nucleus and integrated into the host DNA via the action of 
viral integrase (Zheng, 2005; Fouchier and Malim, 1999).
Host cellular transcription factors (e.g. NF-κβ) are required for transcription of the integrated 
viral genome. These transcription factors are functional when the host cell is in an activated 
state (Hiscott, 2001). The integrated provirus is copied to mRNA, which is then spliced into 
smaller pieces to produce different regulatory proteins (Pollard and Malim, 1998). Structural 
proteins are also produced from full-length mRNA.
Assembly of new HIV-1 virions starts at the plasma membrane of the host cell. The env 
polyprotein, gp160, is processed into gp41 and gp120. Those glycoproteins, together with 
Gag, Pol polyproteins and the genomic RNA, associate to form new virions, which begin to 
bud from the host cell. Further maturation of virions occurs after budding and with the 
formation of active proteases, cleaves Gag and Pol polyproteins into functional subunits 
(Nguyen and Hildreth, 2000).
Figure 2.2. Schematic illustration of the HIV replication cycle. Depicted are - the entrance phase 
(attachment of virus, fusion and penetration in cell); replication and transcription 
phase inside of cell; and budding and maturation of HIV virion.  Sourced online from 
http://www.web-books.com/elibrary/Medicine/Infections/Images/HIV_cycle.jpg
6A number of factors have given rise to the diversity of HIV-1 observed today, including the 
high replication rate and error–prone nature of reverse transcriptase, recombination between 
virus subtypes or virus groups, as well as cross-species transmission (Mansky, 1998; 
McCutchan, 2006). The rapid mutation of the virus is primarily related to error-prone reverse 
transcription at a rate of 1 substitution per genome per replication cycle and the absence of 
any transcriptional safety checks (Sharp et al., 2001; Korber et al., 1998; McCutchan, 2006). 
2.2. HIV: Natural Host, Origin and Diversity
Numerous studies have shown that HIV strains have arisen due to cross-species transmission 
from primates to human beings in Africa (Sharp et al., 2001). The SIVcpz (Simian 
Immunodeficiency Virus [SIV] from chimpanzees), the virus most closely related to HIV-1,
has been isolated from chimpanzees, Pan troglodytes troglodytes (Gao et al., 1999; Corbet et 
al., 2000; Simon et al., 1998). These viruses are non-pathogenic for chimpanzees. Gao et al. 
(1999) observed that the natural range of Pan troglodytes troglodytes, in Western Equatorial 
Africa, coincides uniquely with areas of endemic HIV-1, suggesting that this chimpanzee 
species was the primary reservoir for HIV-1 strains.
The Sooty Mangabey (Cercocebus atys) and the African Green Monkey (Cercopithecus 
aethiops) (AGM) are naturally infected with SIV, but do not develop AIDS like disease 
(Hirsch et al., 1995; Sharp et al, 2001). Phylogenetic analyses indicate that the only species 
naturally infected with viruses closely related to HIV-2 is the Sooty Mangabey from Western
Africa (Chen et al., 1996).
Three groups of HIV-1 have evolved and spread across the globe: M (major), O (outlier) and 
N (new). The M group, which accounts for over 90% of reported HIV/AIDS cases, has been 
further subdivided into 11 subtypes, including A-K, as well as several circulating recombinant 
forms or RCFs (Wainberg, 2004; Requejo, 2006). The viral subtypes show a distinct 
geographical distribution (Figure 2.3; McCutchan, 2006). Subtype C viruses continue to 
dominate worldwide and account for 60% of all HIV-1 infections (Requejo, 2006). In South 
Africa subtype C accounts for more than 90% of all HIV-1 infection. 
The principal means of HIV transmission are through blood, sexual contact or mother-to-child 
transmission (MTCT) (Levy, 2007). 
7Figure 2.3. Global HIV prevalence and distribution. The estimated numbers of HIV-infected 
individuals worldwide are indicated. The colors depict regional patterns of HIV 
variation with different subtypes and recombinant forms distribution (McCutchan, 
2006).
2.3. Pathogenesis of HIV-1 Infection
In absence of treatment, the natural history of HIV infection is divided into 3 major phases 
(Figure 2.4; Kamps and Hoffman, 2007; Levy, 2007):
1 Acute phase (also termed acute viral syndrome or primary HIV infection)
2 Chronic phase (also termed persistent or latency period); 
3 AIDS (also termed symptomatic period).
a. After viral entry into the host, the first stage of primary infection is characterized by 
localized viral replication at the site of entry, usually in the genital tract or rectum. Viruses 
can infect localized CD4 T cells, macrophages or dendritic cells prior to transportation to 
localised draining lymph nodes. Once virus moves from the initial site of entry to the local 
lymph nodes (within 2 days), the infection has become established (Haase, 2005). 
8Following an infection becoming established, there is a dramatic increase in plasma 
viremia and a simultaneous depletion of CD4 T cells. Within 10 to 14 days, up to 200 
billion CD4+ T cells become infected (Embretson et al., 1993). CD4+ T cell numbers 
rapidly decrease during this phase and then return to a level below normal, signifying the 
transition into chronic or persistent infection. CD8+ T cell numbers rise during the viremic 
phase, as is commonly seen in viral infections, and then return to baseline. In acute 
infection cellular immune responses appear to be the first antiviral activity produced (Koup 
et al., 1989), followed later by neutralizing antibodies, which can be detected within days 
to weeks after exposure (Mackewicz et al., 1994; Willey and Aasa-Chapman, 2008). The 
acute phase is also marked by the massive depletion in memory CD4 T cells from gut-
associated lymphoid tissue, which ultimately leads to damage of the gastrointestinal tract 
(GIT) (discussed below and in more detail in Section 2.6).
b. The persistent period or chronic phase begins at resolution of the acute phase at 3 to 6 
months after infection and is characterized by an asymptomatic period with virus 
persistence at low levels in lymph nodes (Siliciano and Siliciano, 2000; Stebbing et al., 
2004). Suppression of HIV replication during this period seems to be mediated by antiviral 
CD8+ cells (Rowland-Jones et al., 1993; Levy et al., 1996) and equilibrium between viral 
replication and host immune response is reached. Even in the absence of treatment, this 
period of clinical latency may last 8-10 years or more (Cohen and Fauci, 2001; Forsman 
and Weiss, 2008). Although chronic infection is asymptomatic, it is a period of chronic 
immune activation (Hazenberg et al., 2003; Asther and Sheppard, 1988). Plasma viral 
loads are generally lower, but rise slowly over time. This is accompanied by a gradual 
decline in CD4+ T cells throughout the latency period (Grossman et al., 2006). A 
heightened state of chronic, systemic immune activation before the onset of AIDS has been 
described by several authors. Chronic immune activation is also associated with damage of 
the GIT, resulting in leakage of the GIT and chronic innate activation due to 
lipopolysaccharides (LPS) and other innate immune stimuli entering the body and/or blood 
stream (Brenchley et al., 2008). The continual presence of antigen is also a driving force in 
the activation process. This prominent feature distinguishes pathogenic infection of 
lentiviruses in humans and macaques from non-pathogenic infection in Chimpanzees, 
AGMs and Sooty Mangabeys (Chakrabarti, 2004; Forsman and Weiss, 2008; Benito, 
2008).
c. Symptomatic period: This phase is usually characterized by CD4+ T cell numbers 
9dropping below 350 cells/µl, increasing viral load and a general reduction in antiviral 
CD8+ T cell responses (Mackewiez et al., 1991; Cao and Walker, 2000). These events 
precede development of AIDS-associated defining clinical illnesses and opportunistic 
infections. Concurrent infections may provoke an increase of immune activation in vivo
and thus accelerate disease progression (Bentwich et al., 2000; Wahl et al., 1999; Sodora 
and Silvestri, 2008). Tuberculosis is the most common major opportunistic infection 
affecting HIV-infected individuals worldwide (Dolin et al., 1994) and cause of death in 
patients at late stage of disease (Mukadi et al., 2001; UNAIDS, 2008). HIV/TB coinfected 
patients display increased expression of cellular activation markers and higher viral loads 
(Goletti et al., 1996).
Figure 2.4. Schematic representation of a typical course of pathogenic HIV/SIV infection. The 
figure shows a persistent increase of immune activation throughout the chronic phase 
of HIV infection. 
From Forsman A and Weiss RA, 2008. doi: 10.10161j.tim.2008.09.004
2.4. HIV-1 Infection and AIDS in South Africa
Subtype C is the predominant circulating HIV-1 strain in South Africa (van Harmelen et al., 
1999; Jacobs et al., 2006), however non-subtype C and recombinant HIV-1 strains are also 
emerging (Jacobs et al., 2007). The majority of HIV transmission in South Africa occurs via 
sexual contact (Jacobs et al., 2007; Rehle et al., 2007).
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In HIV/AIDS epidemiology the term incidence rate is defined as the number of new cases per 
unit of person-time at risk, whereas prevalence rate is a measure of the total number of cases 
of disease in a population (Coggon et al., 1997). Throughout South Africa, geographic 
distribution of HIV infection differs, with the highest antenatal prevalence in 2007 being in 
KwaZulu-Natal (37.4%) and the lowest in the Western Cape (12.6%) (National Department of 
Health, 2008). According to the recent Department of Health report on HIV and AIDS in 
South Africa, HIV prevalence trends suggest a tendency towards stabilization among pregnant 
women since 2004, as seen in the shift from 29.5% in 2004, to 30.2% in 2005, 29.1% in 2006 
and 28% in 2007 (National Department of Health, 2008). Rehle et al. (2007) have reported 
HIV incidence rates of 2.4% in South Africa for the age group 15-49 years with a peak of 
HIV infection among females in the 20-29-year-old age-group at 5.6%, six times greater than 
the incidence found in the male population of the same age group (0.9%). Almost 5.7 million 
people have been reported living with HIV in South Africa at the end of 2007 and 1 000 
AIDS-related deaths occur every day (Pembrey, 2008; UNAIDS, 2008). Since the beginning 
of the HIV epidemic, an estimated 1.8 million people have died of AIDS-related disease in 
South Africa (UNAIDS, 2008). 
The explosive spread of HIV in South Africa is thought to be due to multiple factors, 
including the predominance of circulating HIV-1 subtype C, poverty, higher TB prevalence 
rates, sexually transmitted infections (STIs), other infections, and the limits of government 
action (Pembrey, 2008).
HIV has increased the burden of TB in developing countries (Maher et al., 2005; Lalloo and 
Pillay, 2008). Corbett et al. (2003) reported that South Africa has the largest numbers of co-
infected adults in the world, 2.0 million out of 11.4 million (17.5%) of HIV/TB co-infected 
cases worldwide. In a retrospective study among South African gold miners, the risk of TB 
infection was found to be increased within the first year of HIV infection (Sonnenberg et al., 
2005). On the other hand, HIV/TB coinfected patients respond differently to TB treatment as 
seen with TB drug malabsorption and treatment failure with standard regimens (Gurumurthy 
et al., 2004) This can potentially increase the risk of acquiring or amplifying TB drug 
resistance, including MDR (multidrug-resistant) TB and XDR (extensively drug-resistant) TB 
in South Africa (Andrews et al., 2007). 
Although the introduction of a structured ARV therapy programme in South Africa started in 
2004, its coverage was still only 28% of people in need of treatment at the end of 2007 
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(Pembrey, 2008; WHO, 2008). Prevention campaigns through different media have also been 
launched since 1994 to educate people about HIV infection in South Africa (Noble, 2008). A 
programme to prevent mother-to-child transmission (PMTCT) has been in place countrywide 
since 2003. PMTCT involves prevention of HIV transmission from HIV positive mothers to 
their infants during pregnancy, labour, delivery and breastfeeding by the use of ARVs and 
safer infant feeding practices (Noble, 2008).
More commitment and improved care is required from the government in order to control the 
HIV epidemic in South Africa. A change of government policy in 2008, as stated by the new 
health minister, with an enhanced commitment to ARV distribution, will undoubtedly help to 
address some of the problems faced in the battle against HIV/AIDS in the country.
2.5. HIV-1 Coreceptors
2.5.1. Discovery of HIV Coreceptors
HIV coreceptors are members of the 7-transmembrane G protein-coupled receptor family of 
chemokine receptors whose physiologic role is to transmit cellular signals following 
interaction with chemoattractant cytokines (See Figure 2.5). 
The primary cellular receptor for HIV entry is CD4 (Dalgleish et al., 1984). However, 
expression of CD4 on a target cell is required, but not sufficient for HIV entry and infection. 
Several chemokine receptors are known to allow HIV entry when co-expressed with CD4 on 
the cell surface (Dimitrov et al., 1998). In 1996, chemokine receptors CXCR4 and CCR5
were identified as the major coreceptors for HIV-1 entry (Feng et al., 1996). CXCR4 (also 
referred to as CD184 or Fusin) is the natural receptor for SDF-1 (or CXCL12). CCR5 (also 
referred to as CD195) is the natural receptor for RANTES, MIP-1 and MIP-1 (or CCL5, 
CCL3 and CCL4, respectively).
Prior to identification, the first indication that chemokine receptors might function as 
coreceptors for HIV-1 entry came from observations that the chemokines RANTES, MIP-1
and MIP-1 suppressed infection of susceptible cells in vitro by macrophage-tropic primary 
HIV-1 isolates (Cocchi et al., 1995).
Initial work on HIV-1 coreceptor activity indicated that:
- The chemokine receptor CXCR4 was found to support infection and cell fusion of CD4+ 
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cells by laboratory–adapted T-tropic HIV-1 strains.
- CCR5 was subsequently identified as the principal coreceptor for primary macrophage-
tropic strains.
- CCR3 and CCR2b were also identified as coreceptors that supported infection by some 
strains of HIV-1.
Figure 2.5. Primary sequences and predicted membrane topology of the HIV-1 coreceptors 
CXCR4 (A) and CCR5 (B) (Dimitrov et al., 1998).
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The major coreceptors, CCR5 and CXCR4 (Princen and Schols, 2005; Dimitrov et al., 1998; 
Moore et al., 1997), play a prominent role in the transmission of HIV and during disease 
progression towards AIDS. CCR5 is predominantly expressed on dendritic cells, macrophages 
and CD4 T cells, whereas CXCR4 is expressed on activated T cells (Zhang et al., 1998; Bleul 
et al., 1997). Additionally, T-cell lines express CXCR4, monocytes/macrophages express 
CCR5 and primary T-cells express either or both chemokine receptors.
The distinct tropisms of different HIV-1 isolates for various CD4 positive human target cell 
types were observed in vitro. T-tropic virus strains are those adapted for growth in 
transformed T-cells and which can also replicate in transformed T-cell lines. M-tropic virus 
strains are those viruses adapted in peripheral blood mononuclear cells (PBMCs) and which 
can replicate in cells from the macrophage/monocyte lineage. Both T- and M-tropic viruses 
replicate in activated T-cells. T-tropic strains preferentially use CXCR4 and are syncytium 
inducing (SI), M-tropic strains use CCR5 and are non-syncytium inducing (NSI). Dual tropic
virus strains use both coreceptors (Princen and Schols, 2005; Moore et al., 2004).
Viral isolates obtained from HIV-1 infected persons in the early stages of infection are 
predominantly M-tropic, while those found at a later stage of disease progression towards 
AIDS are mostly T-tropic (Berger et al, 1999; Princen and Schols, 2005).
The minor coreceptors of HIV-1 were also found to mediate the entry of HIV-1 strains in 
vitro and include CCR3 (CD195), CCR8, CCR9, CCR2b (CD192), CX3CR9, CXCR6 
(STRRL33/Bonzo), APJ, and GPR15/Bob. These coreceptors do not play a critical role in 
HIV infection (Princen and Schols, 2005). 
2.5.2. Coreceptor Mediation of HIV Entry
HIV binds to CD4 antigen on cells, such as T helper lymphocytes or macrophages, via the 
HIV surface glycoprotein, gp120. The interaction of gp120 and CD4 antigen causes a 
conformational change in gp120, which is stabilized by the chemokine co-receptor (Dimitrov 
et al., 1998). This causes gp41 to undergo a conformational change exposing hydrophobic 
regions that are then embed in the membrane of the host cell. The viral membrane of the virus 
can fuse with the host membrane and allow the nucleocapsid (containing the RNA genome) to 
enter the cell cytoplasm. 
In brief, the HIV entry process includes the following 3 steps (Figure 2.6):
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- Binding of the viral envelope glycoprotein with CD4 receptor.
- Binding of the envelope-CD4 complex to chemokine receptor, and 
- Fusion of the viral and cell membranes.
Figure 2.6. Schematic presentation of the HIV-1 entry process. This figure displays 3 prominent 
steps of HIV entrance: Binding of Viral envelope glycoprotein with CD4 followed by 
the envelope-CD4 complex binding to chemokine receptors and fusion of the viral and 
cell membranes. (Princen and Schols, 2005).
2.5.3. Relationship between HIV Coreceptors and HIV Pathogenesis
The most significant variables influencing the efficiency of viral entry are both CD4 and 
coreceptor cell surface expression levels (Liu et al., 1996; Doms and Peiper, 1997; Reynes et 
al., 2003). The activity of HIV-1 coreceptors seems to be a critical determinant of disease 
progression (Berkowitz et al., 1998). CCR5 appears to be important for NSI strains of HIV 
(strains most common in early disease), while CXCR4 appears to be more important for SI 
strains (a more aggressive strain sometimes seen in patients with more aggressive disease). 
A homozygous genetic defect resulting in a 32 base pair deletion (32) in CCR5 correlates 
strongly with protection against HIV-1 infection in vivo and in vitro (Liu et al., 1996). 
Individuals who are heterozygous for a defective CCR5 allele are at best weakly protected 
against infection and have only a moderately slowed disease progression. 
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NSI strains of HIV are the most common sexually transmitted form of the virus. It has been
argued that R5 viruses are preferentially transmitted because of the patterns of expression of 
coreceptors and their ligands in memory T cells at mucosal sites after virus deposition during 
sexual intercourse (Moore, 1997; Moore et al., 2004; Philpott, 2003). 
Expression of the two major coreceptors (CCR5 and CXCR4), as well as their respective 
chemokines, appears to be critical in determining T-cell susceptibility to HIV-1 infection 
(Giovannetti et al., 1999; Taylor et al., 2001; Schmitt et al., 2003). Chemokines, as natural 
chemokine receptor ligands, block HIV-1 binding to the chemokine receptors and thereby 
impede viral entry into cells (Bleul et al., 1996; Cocchi et al., 1995).
There is a switch in coreceptor usage during the course of infection in 50% of infected 
individuals from predominance of CCR5-using strains at the early stage of infection, to 
CXCR4-using HIV variants at the late stage of disease (Berger, 1998; Philpott, 2003; Moore 
et al., 2004). The depletion of CCR5 expressing memory cells in acute infection may drive 
viral evolution towards CXCR4 (Moore et al., 2004). This pattern is not a universal 
phenomenon, but rather a tendency in non-subtype C (predominantly subtype B) infection 
(Cilliers et al., 2003).
T cell-associated expression of CCR5 was found to be upregulated in HIV-1 infected 
individuals, while CXCR4 appears downregulated on both CD4 and CD8 T cells when 
compared to normal controls (Giovannetti et al., 1999; Bleul et al., 1997; Ostrowski et al.,
1998). Analysis of chemokine receptor expression patterns shows that CCR5 and CXCR4 are 
differentially expressed on naïve and memory T cells (Blaak et al., 2000). R5 virus tropism 
for memory cells and X4 virus for naïve cells may drive the evolution of phenotypes with 
disease progression (Giovannetti et al., 1999; De Roda Husman et al., 1999; van Rij et al.,
2000; Gorry et al., 2004).
2.5.4. Implications for HIV Therapy
The discovery of HIV-1 coreceptors has stimulated new efforts for identification of entry 
inhibitors, which would prevent the coreceptor interactions with the env-CD4 complex, and 
thus prevent membrane fusion and viral entry (Dalgleish et al., 1984). The best CXCR4 
antagonists described are Bicyclam derivatives, which consistently block X4, but also R5/X4 
viral replication in PBMCs (Princen and Schols, 2005; Schols et al., 1997). Maraviroc is one 
of the small-molecule CCR5 inhibitors currently in ongoing clinical development (Dorr et al.,
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2005).
Both CXCR4 and CCR5 chemokine coreceptor inhibitors will have to be administered 
simultaneously and possibly even in combination with other ARV drugs that target other 
aspects of the HIV replication cycle to obtain optimal antiviral therapeutic effects (Princen 
and Schols, 2005).
A concern with regard to coreceptor inhibitors is whether the inhibition of the normal 
physiological functions of CCR5 will be tolerated or whether blocking this receptor will have 
special adverse consequences in individuals with HIV-related immune impairment (Lederman 
et al., 2006; Kuhmann and Hartley, 2008). It is also unclear if blocking CCR5 in vivo will 
lead to the emergence of resistance to this class of coreceptor inhibitor or in a shift toward 
CXCR4-using strains (Blanpain C, 2002; Princen and Schols, 2005).
2.6. Dynamics of CD4 T Cell Distribution, Activation and Proliferation in HIV-1 
Infection
T lymphocytes can be classified according to their maturation status or antigen experience 
into naïve (N) cells (those that have not yet encountered cognate antigen), effector (E) cells 
(those that have met their antigen, have become activated and differentiated further into fully 
functional lymphocytes) and memory (M) cells (those that have been activated by antigen and 
differentiated for long-lasting immunity). In primary response to new viral infection, naïve T 
cells become activated in lymphoid tissue and differentiate into effector T cells, which then 
migrate to peripheral sites to orchestrate viral clearance. Memory cells respond rapidly on re-
exposure to the antigen that originally induced them (Verhoeven et al., 2008). Memory cells 
are divided into two subsets - effector memory (EM) cells, which are located primarily in 
mucosal tissues, and central memory (CM) cells, which are located in lymphoid tissue (Figure 
2.7). During viral infection, EM cells present an immediate, but not sustained, defence at 
pathogen sites of entry, whereas CM T cells maintain the response by proliferating in the 
secondary lymphoid organs and producing a supply of new effectors (Halwani et al., 2006). 
Central memory T cells are thought to be responsible for the long-term maintenance of 
immune memory. A preserved CD4+ T Central memory cells and activated EM CD4+ T-cell 
subsets have been associated with HIV disease progression (Potter et al., 2007). Previous 
reports have shown that loss of central memory CD4+ T cells during primary SIV mac 251 
infection associated with plasma viral load ( Karlsson et al., 2007; Sun et al., 2007). 
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Furthermore the survival in vaccinated SIV-challenged monkeys was associated with 
preserved central memory CD4+ T lymphocytes and could be predicted by the magnitude of 
vaccine-induced cellular immune response (Letvin et al., 2006). Mason et al. (2008) also 
found a significant association between preservation of CM CD4+ T cells and control of 
viremia in SIV-infected pigtail macaques. 
Markers such as CD45RA, CD45RO, CD27, CCR7 and CD62L have been used to define 
memory cells phenotypically (Figure 2.8). Various researchers have proposed schemes in 
which T cell subsets are defined based on the presence of various combinations of these 
receptors. Most work on memory cells has been on CD8 T cell memory rather than CD4 T 
cells, but schemes used for CD8 T cells have generally been applied to CD4 T cells as well. 
The most common marker combinations include:
- CD45RA+/CD62L+ (N); CD45RO+/CD62+ (M) (Giovannetti et al., 1999; Seder and 
Ahmed, 2003)
- CD45RA+/CD62L+/CCR7+ (N); CD45RO+/CD62+/CCR7+ (CM) (Seder and Ahmed, 
2003; Sallusto et al., 1999)
- CD45RA-/CD62L+ or CD45RA-/CD62- (M) (Giovannetti et al., 1999; Bell et al., 1998)
- CD45RA+/CD45RO-(N); CD45RA+/CD45RO+ (M) (Tortajada et al., 2000)
- CD45RA-/CD62+/CCR7+ (CM); CD45RA-/CD62+/CCR7- (EM) (Seder and Ahmed, 
2003; Sallusto et al., 1999); 
- CD45RO-/CD27+ (N); CD45RO+/CD27+ (CM); CD45RO+/CD27- (EM) (Di Mascio et 
al., 2006).
These markers have natural functional activities, for example CD45 RA/RO is involved in 
modulation of T cell receptor signalling; CD62 is associated with homing to lymphoid tissue; 
and CCR7 is a chemokine receptor for lymphoid homing. Newer classification schemes 
include use of markers such as CD127 (part of receptor for IL-7) and Bcl-2 (cell survival).
18
Figure 2.7. T cell differentiation into CM and EM subsets. This figure displays a differentiation of 
naïve T cell after exposure to an antigen into memory T cells and effector T cells. 
Memory T cells in turn differentiate into central memory and effector memory. 
Memory T cells can also arise from activated effector cells. (Murphy et al., 2008).
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Figure 2.8. Changes in marker expression when naive T cells become memory T cells. This figure 
lists a selection of different markers that can be used to define memory T cells. 
(Murphy et al., 2008).
In natural HIV infection, the major feature of the acute phase is a massive loss of CD4 T cells 
(particularly of the mucosal-associated EM subset) residing in the lamina propria of the GIT 
(Paiardini et al., 2008). These cells are highly susceptible to viral infection, as they express 
CCR5 co-receptor molecules and are readily activated (Douek et al., 2002; Douek et al.,
2003).
The GIT CD4 T cell depletion requires some viral spread, as this is distal to the genital 
mucosae where initial HIV-1 infection usually occurs. The massive depletion of these cells is 
accompanied by a simultaneous loss of peripheral CD4 T cells and a massive increase in 
plasma viral load. Although the peripheral CD4 count recovers after acute infection, the EM 
population is not replenished and antigen is never totally eliminated due to viral integration 
into host cells (Douek et al., 2003; Munier and Kellerher, 2007; Brenchley et al., 2004; Veasy 
et al., 1998; Paiardini et al., 2008).
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Chronic infection is characterized by persistent T cell activation – a feature linked to 
continual antigen presence and also more recently linked to chronic innate immune activity 
due to GIT damage. Continual onslaught by various pathogens is also believed to occur as the 
protective EM cells are no longer present and cannot control infections or antigen level. The 
massive depletion of memory cells from the GIT leads to damage and loss of GIT integrity. 
This may lead to leakage of gut antigen (e.g. LPS seen in HIV) – in turn leading to innate 
immune activation and a chronic stimulation of the whole immune system (Brenchley et al.,
2008; Brenchley et al., 2006). This continual activation ultimately leads to T cell dysfunction 
and impaired functional activity (proliferation, cytokine production, CTL activity) (Appay 
and Sauce, 2008). Chronic HIV is also accompanied by enhanced levels of apoptosis of T 
cells, most likely due to increased Fas and FasL expression in activated T cells, i.e. bystander 
cell death as opposed to direct viral-associated cytotoxic effects (Appay and Sauce, 2008; 
Gougeon, 2005). 
Different subsets of T cells are thus affected in different ways in natural HIV infection. This is 
related to susceptibility to viral infection (related to CD4, co-receptor expression and 
activation status) and also responses generated in order to restore T cell balance after the acute 
phase damage. 
CD4 EM cells are the most susceptible subset for transmission of HIV from dendritic cells 
(Groot et al., 2006). CD4 EM cells are also more susceptible to CTL killing than CM, N or E 
subsets (Liu and Roederer, 2007). Even if new EM cells are generated, they remain the 
primary target for destruction; hence the inability to restore the population and normal 
immune status in HIV patients. Destruction of a large proportion of memory T cells is now 
acknowledged to place a huge immunological burden on the host from which it never 
recovers (Guadalupe et al., 2003; Hazenberg et al., 2000). Interestingly, primate species 
naturally infected with SIV and not displaying any disease pathology, tend to have a much 
lower number of CCR5 expressing cells (Veazy et al., 2000; Chase et al., 2006).
The mere entry of virus into a T cell is not sufficient for viral replication. The cell must also 
divide. Without cell division, viral products are broken down and thus no productive infection 
is possible (Davenport et al., 2002; Stevenson et al., 1990). The viral production from naïve 
cells is much lower than viral production from memory cells. It is possible that high division 
rate of memory T cells compared to that of naïve T cells in an infected host provide an 
advantage for a memory cell-tropic (R5) virus at the early stage of infection (Davenport et al.,
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2002; McCune et al., 2000). 
CCR5 expression on CD4 T cells has been associated with other measures of disease 
progression, such as viral load and CD4 count (Shang Hong et al., 2005; Lin et al., 2002), and 
markers of cellular activation, such as CD38 (Giovannetti et al., 1999; Nicholson et al., 2001; 
Shang Hong et al., 2005). Cellular activation is also known to be critical for productive HIV-1 
infection (Stevenson et al., 1990; Oswald-Richter et al., 2004). Different cellular markers of 
T-cell activation include CD38, CD69, CD95, Ki67, HLA-DR, and loss of CD127 (Appay 
and Rowland-Jones, 2002; Savarino et al., 2000; Kestens et al., 1992; Ziegler et al., 1994; 
Kiazyk and Fowke, 2008; Shepard et al., 2008).
Previous studies have shown consistent increase of viral load when the immune system of 
HIV-1 infected individuals is activated by exogenous stimuli, such as opportunistic pathogens 
(Zhang Zi-ning et al., 2006; Shang Hong et al., 2005; Cohen Stuart et al., 2000). A decline of 
CD4+ T cells is also strongly associated with an increased level of activation markers on CD4 
populations (Savarino et al., 2000; Sousa et al., 2002). T cell activation is one of the 
important factors determining survival of HIV-1 infected patients, with lower activation being 
protective (Hazenberg et al., 2003; Mahalingan et al., 1993). There is a strong interaction 
between HIV replication and T-cell activation, because productive HIV infection is largely 
restricted to activated CD4+ T cells (Stevenson et al, 1990; Cohen Stuart et al., 2000; Zack et 
al., 1990). Persistently increased expression of chemokine receptors and their ligands in HIV-
1 coinfection with active TB may further provide a potential mechanism for increased HIV 
replication, and may contribute to the persistence of immune activation and HIV viremia 
observed in African cohorts (Morris et al., 2001; Sodora and Silvestri, 2008; Wolday et al.,
2005; Rosas-Taraco et al., 2006). Several groups have demonstrated that immune activation is 
central to CD4 cell depletion in HIV infection and immune reconstitution during HAART 
treatment (Anthony et al., 2003; Hazenberg et al., 2000; Benito et al., 2005; Aiuti and 
Mezzaroma, 2006).
2.7. Effect of Antiretroviral Therapy on HIV Coreceptor Expression, Activation 
Status and T Cell Subset Distribution
The function of ARV treatment is to suppress or stop retroviral replication and since the most 
important human retrovirus infection is HIV, the term usually refers to anti-HIV drug 
treatments. In practice, approved ARV agents refer to anti-HIV drugs in clinical use (De 
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Clercq, 2004). The first ARV drugs were introduced between 1987 and 1990, but showed 
modest successes since approaches were focused on monotherapy (use of a single drug). AZT, 
the first ARV introduced early in 1987, did not provide durable efficacy (Hoffman and 
Mulcahy, 2007; Concorde, 1994). The same scenario emerged from the other nucleoside 
analogues (ddC, ddI and d4T) introduced somewhat later as monotherapies. Then in June 
1996, at the World AIDS Conference in Vancouver, the new concepts of “AIDS drug 
cocktails” and HAART emerged, which refers to the combination of 3-antiretroviral drugs. 
Approved ARV drugs currently in use (Hoffman and Mulcahy, 2007; De Clercq, 2004) are:
1. ARV drugs targeting the reverse transcriptase (RT) enzyme at the transcription step of 
HIV replication. These include Nucleoside analogue reverse transcriptase inhibitors 
(NRTIs) e.g. Zidovudine (AZT), Didanosine (ddI), Stavudine (d4T), Lamivudine 
(3TC); Nucleotide analogue inhibitors (NtRTIs) e.g. Tenofovir (TDF); Non-nucleoside 
RT inhibitors (NNRTIs) e.g. Nevirapine (NVP) and Efavirenz (EFV).
2. ARV drugs that target the virion packaging step of HIV replication, including Protease 
inhibitors (PIs) e.g. Saquinavir (SQV), Atazanavir (ATV), Lopinavir (LPV/r) and 
Ritonavir (Norvir).
3. Viral entry inhibitors (VEIs) including Enfuvirtide (T-20) and Maraviroc (MVC).
Current first line approaches (initial regimens) consist of two NRTIs combined with a boosted 
PI, an NNRTI or a third NRTI (Hoffman and Mulcahy, 2007).
Although there has been an increase in the availability of ARV agents over the last few years, 
the selection of optimal combination regimens that could eliminate HIV-1 replication 
continues to be challenging, because of the development of HIV-1 drug resistance (Hanna and 
D’Aquila, 2001; van Vaerenbergh, 2001; Rodes et al., 2005) and also the continued presence 
of low-level viral antigen even when “undetectable” in standard diagnostic tests.
In South Africa, the ARV treatment programme in the public sector which started in 2004 use 
the following recommended treatment guidelines for Adult HIV positive patients (National 
Department of Health South Africa, 2004):
1 Regimen 1a (for all men and for women on contraception): d4T / 3TC / Efavirenz
2 Regimen 1b (for women who are unable to guarantee reliable contraception while on 
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ARV): d4T / 3TC / NVP
3 Regimen 2 (patients with treatment failure despite demonstrated adherence): AZT / ddI / 
Lopinavir.
HAART treatment of HIV-infected individuals result in a decrease in plasma viral load, an 
increase in peripheral CD4 count and a decrease in general T cell activation (Collier et al.,
1996; Autran et al., 1997; Autran et al., 1999). The level of T cell apoptosis is also markedly 
reduced and proliferative capacity increased (Autran et al., 1997). Rebound or persistent 
viremia in patients on HAART is usually linked to development of drug resistant mutations. 
In some cases, however, increased viral load may be due to non-compliance (treatment 
interruption), adverse drug interactions or drug compartmentalization (Bezemer et al., 2006). 
Rebound or persistent viremia is generally accompanied by a decreasing CD4 count and an 
increase in T cell activation; however in certain cases a discordant CD4 increase or 
maintenance of existing CD4 count accompanies viremia (Price et al., 2003; D’Ettorre et al.,
2002).
Since HAART results in a broad inhibition of immune activation, normalization of CCR5 and 
CXCR4 expression after prolonged suppression therapy appears to be linked to reduced levels 
of immune activation (Anderson et al., 1998; Nicholson et al., 2001; Pierdominici et al.,
2002; Brito et al., 2007). Peripheral redistribution of naïve/memory T cell compartment and 
decrease in the level of T cell activation have initially been suggested to be responsible for the 
change observed in coreceptor expression after HAART (Giovannetti et al., 2001; Brito et al.,
2007; Smith, 2002). In contrast, Briz et al. (2008) recently working on a longitudinal cohort 
for 2 years did not find a significant change in coreceptor expression after HAART treatment.
Previous studies have found T cell turnover in HIV infection related to immune activation 
(Hazenberg et al., 2000; Galati and Bocchino, 2007). Anthony et al. (2003) demonstrated a 
direct relationship between activation and proliferation of T cells. Increased turnover of T 
cells in HIV infection is associated mainly with immune activation even after long-term 
HAART, suggesting that T cell activation and turnover play a prominent role in CD4 
depletion in HIV infection and influence the potential for T cell normalization after treatment. 
A study on factors influencing T-cell turnover in HIV-1 patients by McCune et al. (2000),
showed normalization of circulating T cell turnover as a function of time after therapy. After 
3 months of ARV, this turnover still remained high, but normalized at 12-36 months.
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Tortajada et al. (2000) have confirmed that immune reconstitution of T cell subsets after 12 
months of HAART was more likely to occur when treatment was initiated in early stages of 
HIV infection rather than at late stage of disease. Delobel et al. (2006) compared the 
virological and immunological features of 2 groups of patients, one having poor CD4+ T cell 
restoration despite sustained virological responses, and the second having good 
immunological and virological responses. They found X4 viruses playing a role in the 
pathogenesis of poor immune reconstitution on HAART by enhancing T-cell activation and 
bystander apoptosis via gp120-CXCR4 interactions, leading to naïve T-cell depletion. This 
possibility must be considered in future when therapeutic strategies using CCR5 entry 
inhibitors reach clinical application.
Development of drug resistance is important, as mutated viruses do not respond to existing 
treatment regimens. It appears as if different viral subtypes have different levels of mutation; 
possibly due to viral fitness, replication potency and other factors. Transmission of mutated 
viruses is problematic, as newly infected individuals will be non-responsive to treatment. 
Transmitted mutated viruses appear less fit, but appear to maintain cytopathogenicity 
(Solomon et al., 2005). Although transmitted mutated viruses are associated with exacerbated 
CD4 depletion in early acute infection (due to drug unresponsiveness), in later infection this 
does not appear detrimental. In fact, mutated viruses are associated with reduced immune 
activation, which may confer some long-term protection (Hunt et al., 2006; Shet and 
Markowitz, 2006).
The levels of T cell activation and apoptosis in rebound or persistent drug resistant viremia 
may be lower than in acute infection or chronic untreated (no HAART) viremia (Hunt et al.,
2006). This may be due to reduced viral fitness and replication efficiency. Interestingly, it has 
also been documented that drug resistant viruses may be more replication competent and 
pathogenic than wild type viruses (Solomon et al., 2005). Despite all those findings, it is still 
unclear why discordant immunologic and virologic responses occur during HIV ARV 
therapy.
2.8. Impact of Tuberculosis on the HIV-1 Epidemic in South Africa
Mycobacterium tuberculosis (MTB) infection is the most common opportunistic coinfection 
and cause of mortality in people living with HIV/AIDS. An estimated 13% of AIDS deaths 
worldwide are related to TB disease (UNAIDS, 2008). HIV infection also predisposes an 
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individual to reactivation and progression of active TB (Corbett et al., 2003; Djoba Siawaya 
et al., 2007; Toossi, 2003; Badri et al., 2001). It primarily involves macrophages (the target 
cell for TB) and TH1 CD4 T cells. The bacteria reside in macrophages and drive a CD4 TH1 
response as the host attempts to kill the pathogen via T cell-induced activation and/or 
destruction of infected macrophages (Boom et al., 2003; Schluger and Rom, 1998). Thus, in 
TB the presence of high numbers of activated CD4 T cells is ideal for the replication of HIV.
TB provides a milieu of continuous cellular activation that is accommodating to HIV 
replication (Toossi, 2003), consequently enhancing HIV disease progression (Badri et al.,
2001; Collins et al., 2002; Whalen et al., 1995). On the other hand, HIV fuels the TB 
epidemic due to the overlap of these two populations. In Sub-Saharan Africa, the spread of 
HIV has undoubtedly increased the incidence of TB (Lawn et al., 2006; Badri et al., 2001). 
Previous studies have confirmed the interaction between the HIV and TB epidemics by 
showing an increased prevalence of HIV infection among people with TB disease and an 
amplification of TB infection rate in people living with HIV/AIDS (Corbett et al., 2003; Badri 
et al., 2001; Wood et al., 2000). Recently, MacPherson et al. (2009) have reported TB as the 
main cause of deaths (44.3%) in public-sector patients, initiating HAART in a South African 
rural under-resourced region. 
Although ARV therapy leads to reduction of AIDS-related opportunistic infections and 
mortality (Palella et al, 1998; Hung et al., 2003; Dheda et al., 2004; Breen et al., 2006; Badri 
et al., 2002), HIV/TB coinfected patients experience adverse effects that can result in poor 
adherence and failure of therapy (Dean et al., 2002; Burman and Jones, 2001). Also ARV 
may amplify the presentation of active TB due to TB inflammatory reaction of immune 
reconstitution syndrome (IRIS) (Breen et al., 2006; Dhasmana et al., 2008). TB IRIS can be 
observed in two different situations: either unrecognized active TB may be unmasked early 
after initiation of ARV or a known TB patient on anti-TB treatment may develop a 
deteriorating clinical picture after the introduction of ARV (Djoba Siawaya et al., 2007; Lawn 
et al., 2007).
TB treatment involves 6 months of treatment with a 2-month initial phase (with daily or 3 
times weekly isoniazid, rifampicin, pyrazinamide and ethambutol) and a continuation phase of 
4 months (with daily or three times weekly isoniazid and rifampicin) or 6 months (with daily 
isoniazid and ethambutol) (Maher et al., 2005; WHO, 2003b). Rifampicin is a potent inducer 
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of CYP enzymes, producing marked reductions in plasma concentrations of PIs and NNRTI, 
and resulting in drug-drug interactions in concurrent therapy (Niemi M, 2003; Breen et al.,
2006). The implication for HIV/TB coinfected patients treated with a regimen with rifampicin 
throughout is that ARV therapy should be delayed or co-administered using ARV drugs 
compatible with rifampicin (e.g. Efavirenz) (Maher et al., 2005; Niemi et al., 2003).
Patients on TB medication and ARVs are taking a large number of drugs, which may lead to a 
poor adherence of treatment. There is a challenge in concurrent management of HIV/TB 
coinfection with regard to the adverse effects, complex drug interactions, overlapping 
toxicities and IRIS (Beck et al., 2001; Idemoyor, 2007; Breen et al., 2006; National 
Department of Health South Africa, 2004). These problems have promoted the view that anti-
TB therapy should be given initially without HAART (Pozniak et al., 1999; Breen et al.,
2006). Unfortunately in this context, the delay of HAART increases the risk of AIDS events 
or death in advanced HIV/TB coinfected individuals (Dean et al., 2002; Dheda et al., 2004).
In South Africa, treatment guidelines for adult HIV infected patients with concomitant TB is 
as follows (National Department of Health South Africa, 2004):
1. If TB develops while on ARV: continue ARV therapy throughout TB treatment in 
patients on first-line therapy, as previously described. Regimen 1b containing 
Nevirapine should generally be swapped to Efavirenz (because of increased 
hepatoxicity).
2. If TB infection is present before starting ARV: in patients with CD4 count 
>200 cells/µl, start TB treatment and assess the need for ARV after completing TB 
therapy; in patients with CD4 count <200 cells/µl, delay ARV until after 2-months 
intensive phase of TB therapy; in patients with CD4 count <50 cells/µl, introduce ARV 
after no less than 2 weeks of TB therapy.
Balance of logic needs to be established between the risk of progressing AIDS and possible 
death if ARV is deferred, against the risk of adverse events in concurrent therapy. The 
practical therapeutic approach could be to vary the ARV regimen at the time when anti-TB 
treatment is started, in view of the potential drug-drug interactions without interruption of 
antiretroviral therapy. Further studies are required to establish the optimal regimens and 
optimal time at which to start HAART in the context of HIV/TB coinfection. (Breen et al.,
2006; National Department of Health South Africa, 2004).
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In summary, HIV infection is now a major challenge in the control of TB, especially in the 
Western Cape region of South Africa, which has a very high background incidence of TB as 
previously described by Yach, (1988). More studies are needed in such areas to better 
understand the impact of concomitant infections in order to set up strategies for optimal 
management of HIV/TB disease.
2.9. Aim and Objectives of this Study
The aim of this study was to investigate differences in coreceptor expression, immune 
activation status and T cell subpopulation distribution in South African HIV and HIV/TB 
coinfected patients, pre- and post-ARV and also in ARV-responders vs. ARV-non-
responders.
The major objectives of this study were:
1. To determine the expression of HIV co-receptors CCR5 and CXCR4 on CD4+ T cells 
of South African HIV positive individuals pre- and post-ARV treatment
2. To determine the distribution of naïve, effector memory, central memory and effector 
memory CD4 T cell subpopulations in South African HIV positive individuals pre- and 
post-ARV treatment
3. To investigate HIV co-receptor expression on each of the 4 T cell subpopulations in 
South African HIV positive individuals pre- and post-ARV treatment
4. To assess activation status of T cells expressing either CCR5, CXCR4 or both in South 
African HIV positive individuals pre- and post-ARV treatment
5. To determine the effect of TB co-infection on coreceptor expression, T cell subset 
distribution and activation.
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CHAPTER 3:  MATERIALS AND METHODS
3.1. Patient Demographics
Approval for this study was obtained from the Committee for Human Research of the 
University of Stellenbosch (study number N07/08/179). Blood samples were collected from 
Karl Bremer Hospital, TC Newman Hospital and Tygerberg Hospital between April and 
October 2008 by a qualified research nurse. Samples were only collected if patients agreed to 
complete and sign the relevant consent forms. The control (HIV negative) samples were 
obtained from volunteers among Stellenbosch University staff at Tygerberg campus. Their 
status was confirmed by HIV-1 serology and normal CD4 count profiles. 
Venous blood (40 ml) was collected by venipuncture into EDTA vacutainer tubes (BD 
Vacutainer®, Plymouth, UK). Bloods were transported to the laboratory at Medical Virology, 
Tygerberg Campus, Stellenbosch University on the day of collection and processed.
The only inclusion criterion for the study subgroups was HIV positive status, as confirmed 
through routine voluntary counselling and testing (VCT) at the different hospitals.However, 
Healthy controls and TB positive subgroup (newly diagnosed individuals) with HIV negative 
were also included. No specific exclusion criteria were defined for this study. Patients with 
secondary or co-infections, e.g. TB, were not excluded from the study, but formed part of 
unique subgroups. Based on clinical information contained in patient folders as confirmed by 
the clinician, active TB was considered in cases of a clinical diagnosis with appropriate 
radiological evidence of pulmonary TB (PTB) and/or with a positive Ziehl-Neelsen smear 
result for acid-fast bacilli. CD4 count at the baseline was considered as an objective indication 
of the stage of disease.
Cross-sectional analysis was performed on a total of 137 South African individuals, 
comprising 6 groups: 15 healthy normal donors (healthy subgroup), 10 patients with active 
TB (TB subgroup), 33 HIV-1 positive patients without active PTB and treatment naive (HIV 
subgroup), 23 HIV-1 positive patients with active PTB (HIV/PTB subgroup), 36 HIV-1 
positive patients on ARV (HIV on ARV subgroup) and 20 HIV-1 positive patients with active 
PTB on ARV (HIV/PTB on ARV subgroup).
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3.2. Methods
3.2.1. PBMC Isolation
PBMCs were isolated by density gradient centrifugation using Ficoll-Histopaque as first 
described by Boyum (1968). EDTA anticoagulated blood samples were centrifuged at 500 x g 
for 10 minutes to extract plasma (for viral load and HIV serology, see below) and to 
concentrate the cellular fraction. An equal volume of PBS (phosphate buffered saline without 
Ca2+ and Mg2+, Gibco, Invitrogen Corporation, UK) was added to the rest of sample and 
mixed well to dilute the blood. Three milliliters (3 ml) Histopaque®-1077 was added to a 
15 ml conical centrifuge tube (CELLSTAR, Greiner Bio-one, Frickenhausen, Germany). 
Carefully and slowly, 3-6 ml of diluted blood was overlaid onto the Histopaque®-1077. 
Centrifugation was performed at room temperature at 400 x g for 30 minutes (Eppendorf 
centrifuge, Merck, Hamburg, Germany). After centrifugation, the mononuclear cell layer was 
collected at a volume of approximately 1-3 ml per centrifuge tube and washed in 10 ml of 
sterile PBS at 250 x g for 10 minutes. The washing step was repeated, the supernatant fluid 
aspirated and discarded and the cells resuspended in 1 ml of AR10 medium (50% RPMI, 50% 
AIM-V plus 10% heat inactivated FBS) (Gibco, Invitrogen Corporation, UK).
For counting, 15 µl of cells were mixed with an equal volume of Turks solution (0.02% 
crystal violet, 7% glacial acetic acid in water) and cells were counted using a Neubauer 
hemocytometer and microscope (Wild Heerbrugg M20, Switzerland). Cell concentrations 
were adjusted to 5 x 106/ml by centrifugation of the cells and resuspension in the appropriate 
volume of AR10 medium.
Plasma samples were sent to the diagnostic laboratory at Medical Virology, Tygerberg 
Campus, Stellenbosch University on the same day and determination of HIV-1 viral load 
performed on all samples collected from infected individuals.
3.2.2. HIV-1 Viral Load Determination
EasyQ HIV-1 v1.2 is a nucleic acid amplification protocol for the quantitative determination
of HIV-1 RNA in human EDTA plasma. It consists of nucleic acid sequence-based 
amplification (NASBA) combined with a simultaneous real-time detection step using 
molecular beacons on a NucliSens EasyQ analyzer (Yao et al., 2005; de Mendoza et al., 2005; 
Leone et al., 1998).
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Nucleic acid isolation, amplification and detection of plasma viral loads were performed 
according to the manufacturer’s instructions provided with each assay kit. In brief, an 
automated procedure was used for nucleic acid isolation using the NucliSens easyMAG 
magnetic extraction method. Amplification and detection were performed as previously 
described by Yao J et al. (2005). Firstly, 10 µl of primer solution (mixture of synthetic 
primers, synthetic molecular beacon probes, nucleotides, dithiothreitol, KCl and MgCl2) was 
added to a tube containing 5 µl purified nucleic acid extract of each sample. The tubes were 
incubated at 65°C for 2 minutes in a NucliSensQ incubator (Biomerieux, Marcy l’Etoile, 
France) and cooled to 41°C for 2 minutes. Thereafter, 5 µl of enzyme solution was added to 
each tube. Eight-well strip caps (Biomerieux, Marcy l’Etoile, France) were used to seal the 
tubes. All tubes were then transferred to a 41°C temperature controlled NucliSens EasyQ 
analyzer (Biomerieux, Marcy l’Etoile, France) and read 120 times for fluorophores. The 
NucliSens EasyQ Director Software (Biomerieux, Marcy l’Etoile, France) was used to 
quantify viral load in each sample automatically (Yao J et al., 2005; de Mendoza et al., 2005).
3.2.3. HIV-1 Serology
Using AxSYM HIV Ag/Ab Combo (Abbott, Wiesbaden, Germany), a microparticle enzyme 
immunoassay (MEIA), qualitative detection of antibodies to HIV type 1 and/or type 2 and 
HIV p24 antigen in human plasma was performed. AXSYM HIV Ag/Ab Combo is based on 
MEIA technology utilizing recombinant HIV (E. coli) antigens and HIV p24 monoclonal 
(mouse) antibodies coated on microparticles to capture antibodies against HIV-1/HIV-2 and 
HIV p24 antigen. Biotin-labelled recombinant antigens react with captured antibodies/antigen. 
An anti-Biotin alkaline phosphatase conjugate was used to detect the complexes (Kwon et al., 
2006; Sickinger et al., 2004).
A reaction mixture was set up, comprising specimen diluent, sample, and microparticles 
coated with recombinant antigens and monoclonal antibodies in the sample well of the 
reaction vessel (Abbott, Wiesbaden, Germany). In the presence of antibodies or p24 antigen 
in the sample, a complex antigen-antibody is formed on the microparticles. Washing steps 
were performed to remove material not bound to microparticles. Biolabelled recombinant 
antigens were added to form an immune complex revealed with an anti-Biotin alkaline 
phosphatase conjugate, which acts on the substrate to give a fluorescent product measured by 
MEIA optical assembly (Kwon et al., 2006; Sickinger et al., 2004).
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3.2.4. PBMC Surface Staining:
Freshly extracted PBMCs were labelled with fluorochrome-conjugated monoclonal antibodies 
prior to flow cytometric analysis. The following fluorochrome-conjugated antibodies were 
used in the current study: CD4-PerCP (clone SK3, mouse IgG, K; BD Biosciences, San Jose, 
CA, USA), CD45RA-FITC (Clone JS-83, mouse IgG1, K; eBioscience, San Diego, CA, 
USA), CD27-APC (clone 0323, mouse IgG1, K; eBioscience, San Diego, SA, USA), CD38 
(clone H1T2, mouse IgG1, K; eBioscience, San Diego, SA, USA), CCR5-PE (clone R22 / 7 , 
mouse IgG1, K; BD Biosciences, San Jose, CA, USA), CXCR4-PE (12 G5, mouse IgG2a, K; 
BD Biosciences, San Jose, CA, USA), CCR5-APC (clone 3A9, mouse IgG2a, K; 
eBioscience, San Diego, CA, USA).
The staining mixes used in the study allowed characterization of CD4 T cells into Naïve (N, 
CD45+ and CD27+), effector memory (EM, CD45 RA- and CD27-), central memory (CM, 
CD45 AR-, CD27+) and effector (E, CD45 RA+, and CD27-) populations and also allowed 
determination of chemokine receptor expression (CCR5, CXCR4) on CD4 T cells. Activation 
status was determined using CD38. 
Antibodies were used at concentrations previously found to be optimal for lymphocyte 
staining in our laboratory. The first step was to set up different staining mix tubes. Three 
different tubes were prepared to define CCR5 and CD4 subsets (Tube 1), CXCR4 and CD4 
subsets (Tube 2) and CCR5 / CXCR4 and CD4 activation (Tube 3). A total of 
5 x 105 cells/well were labelled with 25 μl of each staining mix. Three sets of staining mixes 
were set up per sample as indicated below. 
Tube 1 Tube 2 Tube 3
CD4-PerCP: 3.5 μl
CD45RA- FITC: 2.5 μl
CD27-APC: 5.0 μl
CCR5-PE: 1.5 μl
Staining buffer: 12.5 μl
Total: 25.0 μl
CD4-PerCP: 3.5 μl
CD45RA-FITC: 2.5 μl
CD27-APC: 5.0 μl
CXCR4-PE: 1.5 μl
Staining buffer: 12.5 μl
Total: 25.0 μl
CD4-PerCP: 3.5 μl
CCR5-FITC: 2.5 μl
CD38-APC: 5.0 μl
CXCR4-PE: 1.5 μl
Staining buffer: 12.5 μl
Total: 25.0 μl
Antibodies were mixed before their use as described. Staining buffer was made using PBS 
without Ca2+/Mg2+ + 0.1% FBS (Foetal Bovine Serum, Gibco, Invitrogen corporation, UK).
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The staining mix volume of each tube had to be multiplied by the number of wells to be 
stained (plus additional to ensure sufficient volume). For example: for 6 wells to be stained 
the staining mix was multiplied by 8. Staining mixes and antibodies were kept on ice during 
the preparation of the cells and staining procedure.
Once staining mixes were prepared, the PBMC pellet of sample was resuspended, 
concentration of cells adjusted to 5 x 106/ml with AR10 medium and plated in 96-well U 
bottomed microtitre plates (CELLSTAR, Greiner BIO-one, Frickenhausen, Germany), at 
100 μl per well, such that a total of 5 x 105 cells were present in each well. One well was 
prepared unstained as a control and three wells for the different staining mixes. Centrifugation 
(Jouan centrifuge GR4.12, Jouan SA, France) of PBMC microtitre plate was performed at 
250 x g (at 8°C) for 5 minutes.
Supernatant was carefully removed using a Gilson pipette (approximately 75 μl) ensuring that 
the pellet remained undisturbed. The pellet was then resuspended by holding microplate on 
vortex. Staining mixes (25 μl) were then added to each well and the microplate incubated at 
4°C for 30 minutes. Initial experiments included isotype control antibody staining, isotype 
controls being used at same volumes as standard antibodies. After staining, 175 μl of staining 
buffer were added to each well and the microplate was centrifuged at 250 x g for 5 minutes at 
8°C. After centrifugation, supernatants were removed, and pellets resuspended on a vortex as 
before. 
Two hundred microliters (200 μl) of staining buffer were added for the second washing step. 
The microplate was centrifuged at 250 x g for 5 minutes, supernatants discarded and pellets 
resuspended on a vortex. Finally, 200 μl of staining buffer was added to each well, and 
contents mixed. Labelled FACS tubes (Falcon, BD Sciences, San Jose, CA, USA) were 
separately filled with 300 μl of staining buffer per tube, wherafter 200 μl of stained samples 
from each well were transferred to the corresponding FACS tube, mixed to make the total 
sample volume to 500 μl per tube and kept at 4°C in the dark until analysed on the Flow 
cytometer.
3.2.5. Whole Blood Staining for CD4 Count
Using BD Multitest reagent CD3-FITC / CD8-PE / CD45-PerCP / CD4-APC, whole blood 
was stained in a TruCount tube containing microbeads to enumerate human T lymphocytes.
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BD-TruCount tubes were labelled with patient numbers and 20 µl of multitest reagent was 
pipetted and deposited with a Gilson pipette above the steel retainer at the bottom of the tube. 
Well-mixed whole blood (50 µl) was added carefully into the bottom of the tube, avoiding 
smearing blood on the side of the tube. The tube was then gently vortexed and incubated for 
15 minutes in the dark at room temperature. 450 µl of 1X FACS lysing solution (BD 
Biosciences, San Jose, CA, USA) was added to the tube and vortexed to mix. Incubation for 
15 minutes in dark at room temperature was performed and the sample was directly analyzed 
on flow cytometer (FACSCalibur, BD Biosciences, San Jose, CA, USA).
3.2.6. Assessment of Coreceptor Expression, Activation Status and CD4 T Cell Subset 
Distribution
3.2.6.1. Acquisition of Data
Using a BD FACSCalibur flow cytometer with CellQuest TM software (BD Biosciences, San 
Jose, CA, USA), acquisition and analysis were performed on stained PBMC samples. Before 
acquiring data, events to be acquired, data storage files and acquisition conditions were 
defined and saved.
Instrument settings and colour compensation values were based on those defined using 
matched isotype control antibodies and the antibody panels defined for the study. Manually 
adjusted (fine tuned) colour compensation settings from these optimization steps were also 
saved. Once settings were optimized, the same settings were used throughout the study. Minor 
adjustments were made to ensure that cells consistently gave the same scatter patters.
The acquisition template for the study had 8 dot plots created for each of the 4 tubes per
sample as described previously. Plot parameters were defined as following: FSC versus SSC 
(FSC / SSC), FL3 / SSC, FL4 / SSC, FL1 / SSC, FL1 / FL4, FL2 / FL4, FL2 / SSC and FL1 / 
FL2 (or FL1 / FL4). Five gated regions were created respectively: G1=R1 (lymphocytes based 
on scatter); G2=R2 (CD4 positive events); G5=R1+R2; G3=R3 (CD4 positive + expressing 
CCR5 or CXCR4); G4=R4 (CD4 positive expressing CD38). Quadrant markers were also 
created on different plots to generate statistics.
Data were acquired as follows: Lymphocytes were identified by gating on forward scatter 
versus side scatter then CD4+ T cells (by gating around CD4-PerCP stained cells). CD38 
expression, CCR5 and CXCR4 expression on total CD4 T cells and different CD4 T cell 
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subsets were determined from different created quadrants. Fifty thousand (50000) of total 
events were acquired per sample. 
3.2.6.2. Analysis of Data
Data was analyzed after acquisition by defining regions and gates, creating quadrant markers 
and generating statistics. For analysis plots, templates of both mean fluorescence intensity 
(MFI) data and percentage positive data (% of cells expressing a particular antigen) were 
used. An example of data analysis for defining cell subsets is given in Figure 3.2.
Figure 3.1. Example of gated regions. A: lymphocytes gated (G1); B: CD4 T cells gated (G2) and 
created quadrants; C: CD4 T cells staining (FL4 vs FL2); and D: CD4 T cells staining 
(FL4 vs SSC).
A B
DC
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Figure 3.2. Example of Characterization of CD4 T cell subset. This plot is based on gating of 
Lymphocytes (FS vs SS) plus CD4 staining (G1 plus G2). Data are expressed as 
percentage (%) of each subset. MFI values for expression of CD45 and CD27 are 
indicated for each subset in parentheses.
Naïve CD45RA+, CD27+; Effector CD45RA+, CD27-; Central Memory CD45RA-, 
CD27+; and Effector Memory CD45RA-, CD27-
3.2.7. Determination of CD4 Count
After defining parameters and instrument settings for BD MultisetTM (BD Biosciences, San 
Jose, CA, USA) data was acquired and absolute cell counts (number of positive cells per µl) 
were determined automatically by the software. Standard procedure was followed for CD4 
count as per accredited SOP (CD4 SOP - SANAS). 
3.2.8. Data Collection and Statistic Analysis
All flow cytometric data were collected into spreadsheet format (Excel). Statistical analysis 
was performed in consultation with a statistician at the Centre for Statistical Consultation, 
Stellenbosch University. 
For comparison of measurements between different subgroups, one-way ANOVA was 
performed. Post-hoc comparisons were done using Fisher least significant difference (LSD). 
To determine relationships between different measurements, Spearman correlations were 
calculated. A 5% significance level (p<0.05) was used as guideline for determining significant 
relationships.
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Where p values are indicated, comparison with uninfected controls is implied (unless stated 
otherwise). P values are scored as follows:
***, p<0.001      **, p=0.001 to 0.01      *, p=0.01 to 0.05    NS, p> 0.05
Graphs: Box and Whiskers graphs show mean, 25th and 75th percentile values (boxes) and the 
error bars represent the 10th and 90th percentiles. 
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CHAPTER 4:  RESULTS
4.1. Demographic, Virological and Immunological Characteristics of Individual 
Subgroups
In this study, a cross-sectional analysis was performed on 137 blood samples collected from 
individual donors comprising different subgroups as described in Chapter 3. Demographic, 
virological and immunological characteristics of the sample collection are shown in Table 4.1.
The median age of individual donors was 35 years (range between 19-65 years), and female 
sex was predominant across all subgroups (Table 4.1). The median duration of treatment was 
6 months in the HIV infected on ARV subgroup, and 2 months and 2 weeks in the HIV/TB 
coinfected subgroup on ARV (data not shown). The median duration of TB treatment was 1 
month in the HIV/TB coinfected subgroup, and 3 months and 2 weeks in the HIV/TB 
subgroup on ARV (Table 4.2).
CD4 count differences were not significant between the HIV subgroup and the HIV/TB 
subgroup without ARV. Median CD4 count in individuals with active TB (in absence of HIV 
infection) was strangely found low when compared to the healthy subgroup (544 Vs 1408), 
however the number of participants with CD4 count data in TB disease subgroup was smaller 
( Table 4.1) than  in the healthy subgroup (7 Vs 15). After initiation of treatment, however, 
the CD4 count was found to be higher in the HIV on ARV subgroup (median 235.5) 
compared to the HIV/TB on ARV subgroup (median 141). The increase of 62 cells/l in the 
HIV subgroup represents a 53.7% enhancement following ARV. In the HIV/TB subgroup, the 
increase following initiation of ARV was 25.5 cells/l, only a 22% enhancement. 
Before ARV treatment, the median viral load was 3.95 fold increased in the HIV/TB 
subgroup as compared to the HIV subgroup (71 000 copies/ml vs. 18 000 copies/ml). The 
median viral load in both the HIV and HIV/TB subgroups on ARV was decreased to 
undetectable limit ( 357 copies/ml). 
4.2. Coreceptor Expression in Individual Subgroups
Due to the important role that CCR5 and CXCR4 coreceptors play in HIV entry and disease 
progression, assessment of their expression on CD4 T cells within the defined subgroups was 
performed. CCR5 and CXCR4 expression on CD4 T cells was determined by immunostaining 
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and flow cytometric analysis of fresh PBMCs isolated from individual blood samples as 
described in Chapter 3. 
Table 4.1. Demographic, virological and immunological characteristics of individuals within 
donor subgroups
Healthy PTB HIV HIV/TB HIV HIV/TB
on ARV on ARV
No of Subjects 15 10 33 23 36 20
Age (median years) 43 42 35 33 37 34
% of Males 37.7 40 27.3 43.5 25 45
% of Females 64.3 60 72.7 56.5 75 55
CD4 count (median) 1408 544* 173.5** 115.5** 235.5 141
Viral Load copies/ml (median) 18000 71000 LDL*** LDL
Log10 copies/ml (median) 4.3 4.9 2.5 2.5
Subgroups: Healthy = normal donors; HIV = HIV infected patients; PTB = active pulmonary 
tuberculosis patients; HIV/TB =- HIV/TB coinfected patients; on ARV = on antiretroviral therapy. 
* 3 CD4 count data not included, median based on n=7. ** 1 CD4 count data not included, median 
based on n=32 (HIV) and n=22 (HIV/TB). ***LDL = lower than detectable limit (≤ 357 copies/ml).
Note: Of total CD4 count data (136) 54 (40%) were performed on fresh blood. Other CD4 data were 
collected from file within last 3 months.
Table 4.2: TB treatment of the individuals with pulmonary TB♦
HIV/TB HIV/TB on ARV
Duration
Pre-treatment 6 6
0-2 months 10 4
More than 2 months 5 7
♦Data are expressed as number of patients with documented TB treatment.  
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The percentage of CD4 T cells expressing CCR5+ and CXCR4+ are shown in Figures 4.1 and 
4.2 and Table 4.3. The percentage CCR5 positive CD4 T cells in the HIV/TB subgroup 
(28.6%) was significantly reduced compared to the HIV subgroup (52.5%, p<0.05), and the 
healthy control group (55.9%, p<0.05). The HIV/TB subgroup also showed reduced 
expression when compared to the PTB subgroup (53%), however this was not statistically 
significant.
The MFI of CCR5 expression on CD4 T cells (Figure 4.1) in the HIV/TB coinfected subgroup 
(median MFI = 64.6) was significantly higher than the HIV infected subgroup (median 
MFI = 46.4; p<0.05) and healthy controls (median MFI = 40.2; p<0.005). As with percentage 
data, the difference of CCR5 level expression in the HIV/TB subgroup was found to be not 
significant compared to the PTB control subgroup. These figures indicate that HIV/TB 
disease leads to a significant additional reduction in the percentage of CCR5 expressing 
CD4+ T lymphocytes compared to HIV alone. The reduced number of CCR5 positive cells is 
accompanied by a significant increase in CCR5 receptor expression per cell.
The percentage of CXCR4+ CD4 T cells (Figure 4.2; Table 4.3) was higher in healthy 
controls (57.9%) compared to all the infected subgroups: PTB (48.9%, p=0.057), HIV (40%, 
p<0.005) and HIV/TB (27.4%, p<0.001). As with CCR5, TB co-infection lead to an 
exacerbated reduction in CXCR4 expressing CD4 T cells beyond that observed in HIV 
infection alone.
The MFI of CXCR4 expression on CD4 T cells (Figure 4. 2) in the PTB subgroup (median 
MFI = 73.3) was significantly higher compared to the HIV/TB subgroup (median MFI = 41.6; 
p<0.005), the HIV subgroup (median MFI = 35.3; p<0.0001) and healthy controls (median 
MFI = 34.3; p<0.001). However, unlike CCR5 expression, CXCR4 expression was not 
significantly increased in the HIV/TB subgroup compared to the HIV infected subgroup 
(p=0.058) and healthy controls (p>0.05). These figures illustrate that HIV/ TB disease was 
associated with exacerbated reduction in CXCR4 expressing cells.
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Figure 4.1. Comparison of CCR5 expression on CD4+ T cells in individuals within donor 
subgroups. PBMCs were stained with CD4-PerCP, CD45-FITC, CD27-APC and 
CCR5-PE. Data are expressed as Means with SEM (standard error of the mean) of 
percentage cells positive for CCR5 and CCR5 MFI (indicating the fluorescence 
intensity of CD4 T cell expressing CCR5+).
A: Reduced percentage of CCR5 positive cells is shown in all infected subgroups, with 
HIV/TB disease the most severely reduced. There was also a significant difference 
between the HIV subgroup (p<0.05) compared to the HIV/TB subgroup
B: CCR5 MFI was increased in all infected groups compared to the healthy control 
group, the PTB subgroup (p<0.05); the HIV subgroup (p<0.01) and the HIV/TB 
(p<0.005) subgroup
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Figure 4.2. Comparison of CXCR4 expression on CD4+ T cells in individuals within donor 
subgroups. Four-colour flow cytometry analysis was performed on PBMC using CD4-
PerCP, CD45-FITC, CD27-APC and CXCR4-PE mAbs. Data expressed as Means 
with SEM.
A: A significant decrease in percentage CXCR4 + in the HIV/TB subgroup (p<0.001) and 
the HIV subgroup (p<0.005) compared to healthy controls
B: A significantly increased CXCR4 expression in the PTB subgroup (p<0.0001) 
compared to the HIV subgroup 
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4.3. Activation Marker Expression in Individual Subgroups
T cell immune activation is crucial in productive HIV infection as HIV preferentially targets 
activated CD4 T cells. To determine the immune activation status of CD4 T cells in the 
different donor subgroups, CD38 expression was measured as a marker of activation.
The median percentage CD38+ CD4 T cells (Figure 4.3 and Table 4.3) was higher in the 
HIV/TB and the HIV subgroups (33.4% and 30.4% respectively) compared to healthy 
controls (23.4%). The immune activation status of CD4 T cells in the PTB subgroup (median 
MFI = 77.5) was significantly higher compared to the HIV subgroup (median MFI = 50.5; 
p<0.05) and healthy controls (median MFI = 43.2; p<0.05). CD38 expression in the HIV/TB 
subgroup (median MFI = 64.2) was significantly higher compared to the HIV subgroup 
(median MFI = 50.1; p<0.005) and healthy controls (median MFI = 43.2; p<0.005).
Expression of CD38 on CCR5- and CXCR4-expressing CD4 T cell subsets was also 
determined. Percentage activated CD4 T cells expressing CCR5+ and CXCR4+ are shown in 
Figure 4.4. Activated CD4 T cells expressing CCR5+ were found to be significantly increased 
in the HIV/TB (72.9%) and HIV subgroups (64.5%) compared to healthy controls (46.5%; 
p<0.005).
Conversely, activated CD4 T cells expressing CXCR4+ did not differ significantly within the 
donor subgroups. In the PTB subgroup, activated CD4 T cells expressing CCR5+, but not 
CXCR4+, were higher compared to healthy controls (79.3% vs. 46.2% CD4+CD38+CCR5+ 
and 50% vs. 56.9% CD4+CD38+CXCR4+).
Table 4.3. CCR5, CXCR4 and CD38 positive percentage of CD4 T cell in Individuals within 
the donor subgroups♦
Healthy PTB HIV HIV/TB HIV HIV/TB
on ARV on ARV
CCR5+ 55.9 53.0 52.5 28.6 69.3 36.8
CXCR4+ 57.9 48.9 40.0 27.4 55.0 32.8
CD38+ 23.4 24.3 30.4 33.4 34.2 31.3
♦ Data are expressed as Median percentage positive CD4 T cells. Subgroups: Healthy, normal 
donors; HIV, HIV infected patients; PTB, active tuberculosis patients; HIV/TB, HIV coinfected 
patients; on ARV, on antiretroviral therapy
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Figure 4.3. Comparison of CD38 expression on CD4+ T cells in individuals within donor 
subgroups. PBMCs were stained with CD4-PerCP, CCR5-FITC, CXCR4-PE and 
CD38-APC mAbs. Data is expressed as Means with SEM.
A: Increased CD4 T cell CD38 expression in the HIV/TB and HIV subgroups compared 
to healthy controls
B: Increased CD38 expression in the PTB (p<0.05) and HIV/TB subgroups (p<0.005) 
compared to the HIV subgroup
43
0
20
40
60
80
100 ***
***
**
% CD4+ CCR5+ CD38+
Uninfected
TB
HIV
HIV/TB
0
20
40
60
80
100
% CD4+ CCR5+ CD38+
* *
Uninfected
HIV
HIV-RV
HIV/TB
HIV/TB-RV
0
20
40
60
80
100
Uninfected
TB
HIV
HIV/TB
CD4+CXCR4+ CD38+
0
20
40
60
80
100
% CD4+CXCR4+ CD38+
Uninfected
HIV
HIV-RV
HIV/TB
HIV/TB-RV
A B
C D
Figure 4.4. Comparison of mean percentage positive activated CD4 T cells expressing CCR5+ 
and CXCR4+. Data expressed in scatter dot plot as means with SEM.
A: Before ARV treatment, a significant increase of activated CCR5+ CD4 T cells in the 
HIV/TB (p<0.005), HIV (p<0.05) and PTB subgroups (p<0.05) compared to healthy 
controls
B: After ARV treatment, a significant decrease of CCR5+ CD4 T cell activation in the 
HIV/TB (p<0.05) and HIV on ARV subgroups (p<0.05) as compared to untreated 
patients
C: Activated CXCR4+ CD4 T cells within different subgroups before ARV treatment did 
not show a significant difference within the subgroups
D: Activated CXCR4+ CD4 T cells within different subgroups after ARV treatment did 
not show a significant difference within the subgroups
4.4. CD4 T Cell Subset Distribution in Individual Patient Subgroups
CD4 T cell susceptibility to HIV infection is related to the mode of HIV transmission and 
activation status of the T cells. Infection with HIV also impacts on T cell subset distribution, 
since certain subsets of cells are more readily infected than others. To phenotypically define 
different CD4 T cell subsets in this study, CD27 and CD45 were used as markers. After 
immunostaining of fresh PBMCs from individual donors, different dot plots were constructed 
and quadrants created to allow characterization of CD4 T cells into naïve, EM, CM and 
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effector cells as described in Chapter 3.
Based on co-expression of two markers (CD27/ CD45), data were depicted as the percentage 
positive-defining CD4 T cell subset populations Distribution of the naïve CD4 T cell, effector 
CD4 T cell, CM and EM CD4 T cell subsets is reported in Figures 4.5 to 4.10 respectively. 
Antigen-experienced cells including non-naïve cells were also calculated by summing 
proportions of effectors, central memory and effector memory CD4 T cells (Figure 4.10).
The percentage of naïve CD4 T cells in the HIV (13.7%) and HIV/TB coinfected subgroups 
(11%) (Figures 4.5 and 4.6) was substantially decreased compared to healthy controls (41.1%; 
p<0.0001). The percentage of effector CD4 T cells was higher in the HIV subgroup (24.9%) 
compared to the HIV/TB (13%, p<0.005), PTB (20.1%) and healthy subgroups (22.1%) 
(Figures 4.5 and 4.7). The percentage of central memory CD4 T cells (Figures 4.5 and 4.8) 
was considerably decreased in the HIV/TB (6.8%, p<0.0001) and HIV subgroups (12.6%, 
p<0.005) compared to healthy controls (20%). The percentage of effector memory CD4 T 
cells were higher in the HIV/TB subgroup (58.9%) compared to the HIV infected subgroup 
(37.7%, p<0.05) and healthy controls (14.6%, p<0.0001). The percentage of antigen-
experienced cells was increased in the HIV/TB subgroup (78.7%) compared to the HIV 
infected subgroup (75.1%) and healthy controls (56.7%, p<0.005).
In addition to subset distribution in peripheral blood, we examined coreceptor expression in 
different CD4 T cell subsets. The effect of ARV on CD4 T cell subsets expressing CCR5+ 
and CXCR4+ was also determined. Data is shown in Figures 4.11 and 4.12, and Table 4.4. 
Within the patient subgroups, as expected, naïve CD4 T cell subsets expressed more CXCR4+ 
than CCR5+, for example 47.7% CXCR4+ vs. 42.6% CCR5+ in healthy controls. The CCR5 
expressing CM subsets were increased in the HIV (16.9%) and HIV/TB subgroups (14.8%) 
compared to healthy controls (9.2%). CXCR4 expression of the naïve T cell subsets were 
decreased in the HIV/TB (24.7%) and HIV subgroups (22.8%) compared to healthy controls 
(47.7%). Expression of CCR5 and CXCR4 on the effector CD4 T cell subset was higher in 
the HIV subgroup (36.8% and 43.7%) compared to the HIV/TB subgroup (29.0% and 29%) 
and healthy controls (28.8% and 26.3%).
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Figure 4.5. Representation of CD4 T cell subset distribution in pie graph format. This figure 
shows different CD4 T cell subset distribution within patient subgroups. Data 
expressed as positive % of Naïve, Effector, Central Memory and Effector Memory 
CD4 T cells.
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Figure 4.6. Distribution of Naïve CD4 T cell subsets in individual subgroups. Phenotypic analysis 
of PBMCs following staining with mAbs was performed. Data expressed as means 
with SEM of percentage positive indicated the number of Naive CD4 T cell subset is 
significantly decreased in the HIV subgroup and HIV/TB subgroups compared to 
healthy controls (p<0.0001).
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Figure 4.7. Distribution of Effector CD4 T cell subsets. After four-colours staining of PBMCs, 
phenotypic analysis was done by FACS. Data expressed as means with SEM of 
percentage positive present the numbers of Effector CD4 T cell subset indicating a 
significant increase in the HIV subgroup (p<0.005) compared to the HIV/TB 
subgroup.
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Figure 4.8. Distribution of Central Memory CD4 T cell subsets. Data are expressed as means with 
SEM. This figure indicates a significant decrease of central memory CD4 T cells in 
the HIV/TB (p<0.0001) and HIV subgroups (p<0.005) compared to healthy controls.
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Figure 4.9. Distribution of Effector memory CD4 T cell subsets. Data are expressed as means 
with SEM. The percentage of effector memory CD4 T cells is significantly higher in 
the HIV/TB subgroup compared to the HIV subgroup (p<0.05) and healthy controls 
(p<0.0001).
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Figure 4.10. Distribution of antigen-experienced CD4 T cell subsets. Data expressed as means with 
SEM. The figure shows a significant increase of antigen-experienced (effector + 
central memory + effector memory) CD4 T cells in the HIV/TB subgroup compared to 
the HIV subgroup (p<0.05) and healthy controls (p<0.0001).
After ARV treatment, CCR5 expression of antigen-experienced subsets were significantly 
decreased in the HIV subgroup (75.3% untreated vs. 67.3% treated, p<0.05), but not in the 
HIV/TB on ARV subgroup (69.2% vs. 78.6%) (Figure 4.11 and Table 4.4).
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Table 4.4
Coreceptor expression of CD4 T cell subsets in Individuals within the donor 
subgroups♦
Healthy PTB HIV HIV/TB HIV HIV/TB
on ARV on ARV
CD4 T cell subset Cell marker
Naïve CCR5+ 42.6 32.3 19.2 22.0 26.9 16.5
Effector CCR5+ 28.8 38.8 36.8 29.0 39.1 38.4
Central Memory CCR5+ 9.2 4.6 16.9 14.8 12.1 14.4
Effector Memory CCR5+ 14.4 19.4 21.6 25.4 16.1 25.8
Antigen-experienced-
cells CCR5+ 52.4 62.8 75.3 69.2 67.3 ♦♦ 78.6♦♦♦
Naïve CXCR4+ 47.7 33.6 22.8 24.7 30.3 17.2
Effector CXCR4+ 26.3 36.9 43.7 29.0 45.6 42.8
Central Memory CXCR4+ 5.6 5.5 6.1 7.4 4.2 6.7
Effector Memory CXCR4+ 18.0 66.5 22.8 31.6 15.6 28
Antigen-experienced-
cells CXCR4+ 49.9 29.6 72.6 68.0 65.4 77.5
♦ Data are expressed as Median of positive percentage. Subgroups: Healthy, normal donors; HIV, 
HIV infected patients; PTB, active tuberculosis patients; HIV/TB, HIV coinfected patients; on 
ARV; on antiretroviral therapy.
Note. Percentage of CD4 T cell subset expressing CCR5+ or CXCR4+ was calculated then 
Median of % determined.  
♦♦ p<0.05 as compared to HIV subgroup.
♦♦♦ p>0.05. Not significant as compared to HIV/TB subgroup.
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Figure 4.11. Representation of T cells subset distribution of CD4 T expressing CCR5+ within 
subgroups. Data expressed in % positive of CD4 T subset expressing CCR5+. Naïve, 
Effector, Central memory and Effector memory subsets are indicated.
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Figure 4.12. Representation of T cells subset distribution of CD4 T expressing CXCR4+ within the 
subgroups. Data expressed in % positive of different subset CD4 T cells expressing 
CXCR4+. Naïve, Effector, Central memory and Effector memory subsets are 
indicated.
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4.5. Comparison of Coreceptor expression, activation marker expression and CD4 T 
cell distribution in the HIV infected and HIV/TB co-infected subgroups 
according to CD4 count level 
CD4 count is one of the classic markers used to define HIV disease progression and to 
monitor ARV treatment. Cut-off for High vs. Low CD4 count comparison in this study was 
200 cells/µl, as this is the CD4 count used as a guide for ARV initiation in South Africa.
Based on the CD4 count cut-off of 200 cells/µl, the HIV infected and HIV/TB coinfected 
subgroups were compared to assess differences in coreceptor expression, activation markers 
and CD4 T cell distribution with regard to the degree of immunosuppression. As information 
on clinical stage of disease within the subgroups was incomplete, this comparison was used to 
help to correlate CD4 level with the severity of immunosuppression with different markers 
expressed on CD4 T cells. The <200 cells/µl CD4 count HIV subgroup including 20 patients 
while the >200 cells/µl CD4 count HIV subgroup was composed by 12 patients. The <200 
cells/µl CD4 count HIV/TB subgroup including 15 patients whereas the >200 cells/µl CD4 
count HIV subgroup was with 7 patients.
The data illustrated in Figures 4.13 and 4.14 indicate that overall numbers of activated CD4+ 
T cells (as measured by CD38 %) was reduced in the <200 cells/µl CD4 count HIV group, but 
the MFI was increased. This seems to point towards a loss of activated T cells, but generally 
more activation marker expression per cell. HIV/TB disease also tended to increase both % 
CD38 positive cells and MFI of CD38 expression. These data were not statistically 
significant, due to the small sample size when stratifying groups based on CD4 count. CCR5 
expression seems to follow a similar pattern to CD38.
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Figure 4.13: Comparison of expression in patients with CD4 >200 cells/µl and CD4 <200 cells/µl
Panel A and B. Comparison of activation marker expression in patients with CD4 
>200 cells/µl and CD4 <200 cells/µl. Data expressed as means with SEM. Higher 
expression of CD38 in the HIV/TB subgroup compared to the HIV subgroup was 
observed in both CD4 subsets.
Panel C. Comparison of CCR5 expression in patients with CD4 <200 cells/µl and 
CD4 >200 cells/µl. Data expressed in means with SEM. Increased CD4 T cell CCR5 
expression in the HIV subgroup compared to the HIV/TB subgroup.
Panel D. Comparison of CCR5 expression in patients with CD4 <200 cells/µl and 
CD4 >200 cells/µl. Data expressed in means with SEM. Increased CCR5 expression 
in the HIV/TB subgroup compared to the HIV subgroup.
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Figure 4.14: Comparison of T cell subset distribution in patients with CD4 count <200 cells/µl. 
Data expressed as means with SEM. Increased effector and central memory CD4 T 
cells indicated in the HIV subgroup compared to the HIV/TB subgroup in graphs A, B 
and C.
Increased effector memory and antigen-experienced subsets in the HIV/TB subgroup 
compared to the HIV subgroup illustrated in graphs D and E.
Comparison of T cell subset distribution in patients with CD4 count >200 cells/µl. 
Percentage of effector CD4 T cells and central memory CD4 T cells in graphs B and C 
are higher in the HIV subgroup compared to the HIV/TB subgroup, whereas 
proportions of effector memory subset, antigen-experienced cells and naïve CD4 T 
cells in graphs A, D and E are higher in the HIV/TB subgroup.
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4.6. Effect of ARV on Coreceptor Expression, Activation Marker Expression and 
CD4 T Cell Subset Distribution in Individual Patient Subgroups
The impact of ARV is largely evaluated by observing changes in the viral load and peripheral 
CD4 count. Little, however, is known of the impact of ARV on coreceptor expression, CD4 T 
cell subset distribution (or redistribution) and CD4 T cell immune activation status, 
particularly in South African individuals. In the current study, an assessment of CCR5, 
CXCR4, CD38 expression and CD4 T cell subset distribution was performed on naive 
patients and patients with treatment to evaluate the effect ARV in HIV infected and HIV/TB 
coinfected patients.
4.6.1. Effect of ARV on Coreceptor Expression, Activation Marker and T Cell Subset 
Distribution
To assess the effect of ARV on coreceptor expression, the levels of CCR5, CXCR4, CD38 
expression and CD4 T cell subset distribution were compared according to the duration of 
ARV treatment within individual subgroups on ARV and without ARV. Data is shown in 
Figures 4.15 to 4.22.
Overall data on the effect of ARV indicates a decrease of CCR5 expression and CD38 
expression (data expressed as means of MFI) after 6 months of ARV within all subgroups 
(not statistically significant); a significant (p<0.05) decrease in CXCR4 expression (data 
expressed as means of MFI) in the HIV/TB on ARV subgroup; % naïve CD4 T cells were 
significantly increased (p<0.05) in the HIV subgroup, but not the HIV/PTB on ARV subgroup 
after ≥ 6 months of treatment. Effector T cells showed a significant increase in the HIV on 
ARV subgroup (p<0.005), but not in the HIV/PTB on ARV subgroup (p>0.05) after ≥ 6 
months of treatment; central memory T cells significantly increased (p<0.05) in the HIV on 
ARV subgroup, but not in the HIV/TB subgroup; Effector memory and antigen-experienced 
CD4 T cells were significantly decreased ( p<0.005 and p<0.0001 respectively) in the HIV on 
ARV subgroup, but not in the HIV/TB subgroup. 
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Figure 4.15: Effect of ARV on CCR5 expression in patients after ≥ 6 months of treatment.
A: Data (expressed as % positive) show CCR5+ CD4 T cells increased (not significantly) 
after ARV in the HIV and HIV/TB subgroups compared to untreated patients.
B: Data (expressed as means of MFI) show CCR5 expression decreased in the treated 
HIV/TB and HIV subgroups compared to the untreated subgroups (p>0.05). 
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Figure 4.16: Effect of ARV on CXCR4 expression in patients after ≥ 6 months of treatment.
A: Mean data indicates increased CXCR4 expression after treatment in the HIV subgroup 
(p>0.05), whereas in the HIV/TB subgroup there is a significant decrease of CXCR4 
expression (p<0.05).
B: Mean data indicates weakly increased CXCR4 expression after treatment in the HIV 
subgroup (p>0.05), whereas in the HIV/TB subgroup there is a significant decrease of 
CXCR4 expression (p<0.05).
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Figure 4.17: Effect of ARV on activation marker in patients after ≥ 6 months of treatment.
A: Mean data shows a minor increase of CD38 expression after ARV treatment in the 
HIV, but not HIV/TB subgroups. 
B: Mean data indicates a decrease of CD38 expression in the HIV on ARV and HIV/PTB 
on ARV subgroups compared to untreated subgroups (p>0.05). 
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Figure 4.18: Effect of ARV on Naive CD4 T cell subsets. Data expressed as % positive indicates a 
significant increase of Naive T cells in the HIV on ARV subgroup (p<0.05), but not 
the HIV/PTB on ARV subgroup (p>0.05) after ≥ 6 months of treatment.
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Figure 4.19: Effect of ARV on effector CD4 T cell subsets. Data expressed as % positive indicates 
a significant increase of effector T cell numbers in the HIV on ARV subgroup 
(p<0.005), but not in the HIV/PTB on ARV subgroup (p>0.05) after ≥ 6 months of 
treatment. 
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Figure 4.20: Effect of ARV on effector memory CD4 T cell subsets. Data are expressed as 
percentage positive and show a decrease in this subset after ≥ 6 months of ARV 
treatment in the HIV subgroup (p<0.005) and the HIV/PTB subgroup (p>0.05).
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Figure 4.21: Effect of ARV on central memory CD4 T cell subsets. Data expressed as percentage 
positive shows the number of central memory T cells increased significantly in the 
HIV (p<0.05) and HIV/PTB subgroups (p>0.05) after ≥ 6 months of treatment.
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Figure 4.22: Effect of ARV on antigen-experienced CD4 T cell subsets. Data expressed as 
percentage positive of antigen-experienced cells indicates a decrease of this subset in 
the HIV on ARV subgroup (p<0.0001), but not the HIV/PTB coinfected on ARV 
(p>0.05) after ≥ 6 months of treatment.
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4.6.2. Comparison of activation marker expression, CD4 T cell subset distribution in 
patients classified as ARV Responders vs. non Responders
Immunological and virological responses observed during ARV treatment allowed for the 
subdivision of HIV patients in two groups: ARV responders and ARV non responders. 
Given that CCR5, CXCR4 and CD38 expression, as well as CD4 T cell subset distribution, 
are affected by ARV treatment, the differences in coreceptor expression, immune activation 
and CD4 T cell subset distribution between ARV responder and ARV non responder 
subgroups was assessed.
Based on the CD4 count and viral load results, HIV on ARV subgroup (in the absence of TB)
after ≥ 6 months was subdivided in 2 different subgroups as follows: ARV Responder -
patients on ARV with CD4 counts ≥200 cells/µl and viral load lower than limit of detection; 
ARV non-Responder - patients on ARV with CD4 counts <200 cells/µl and detectable viral 
load (i.e. higher than limit of detection of 357 copies/ml). Data is expressed as median MFI, 
percentage of activation marker (CD38) and percentage positive of CD4 T cell subsets, and 
are illustrated in Figure 4.23. Comparison of CD38 expression showed ARV non responders 
(means MFI = 56.7; means % 42.3) had higher expression compared to ARV responders 
(means MFI = 43.4; means % 28.1).
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Figure 4.23:A: Comparison of activation marker expression in different groups. Data expressed as 
mean with SEM of MFI revealed an elevated CD38 expression in the ARV non 
responder subgroup 
B: Comparison of naïve CD4 T cell subset distribution. Increased naïve T cell subset 
numbers in the ARV Responder subgroup was observed.
C: Comparison of antigen-experienced CD4 T cell distribution. Increased antigen-
experienced CD4 T cell subset numbers in the ARV non Responder subgroup was 
observed.
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The percentage of Naïve CD4 T cells was higher in the ARV responder (29.2%) compared to 
the ARV non responder (24.2%) subgroups; Antigen-experienced CD4 T cells were higher in 
ARV non-responder (76.2 %) compared to the ARV responder (70.6 %) subgroups. 
Comparison of coreceptor expression in ARV responders vs. ARV non responders did not 
reveal statistically significant differences (data not shown), due to small sample size when 
stratifying groups. ARV responder subgroup including 9 HIV infected patients and ARV non 
responder subgroup with 5 HIV infected patients after ≥ 6 months of therapy.
4.7. Relationship between Coreceptor Expression, Immune Activation and T cell 
Subset Distribution
To assess whether the expression of coreceptors was associated with immune activation 
status, different coefficients of correlation were calculated between CCR5, CXCR4 and CD38 
expression, and CD4 T cell subset distribution within the patient subgroups.
4.7.1. Correlation between Coreceptor Expression and Immune Activation
Significant positive relationships we observed between CCR5 and CXCR4 expression 
(r=0.66, p<0.001), CCR5 and CD38 expression (r=0.59, p<0.001), and CXCR4 and CD38 
expression (r=0.55, p<0.001) on CD4 T cells.
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Figure 4.24: A significant positive relationship was found between CD38 and CCR5 expression 
with Spearman coefficient of correlation (r) =0.059 and p value <0.001.
4.7.2. Correlation between Coreceptor Expression, Immune Activation, Viral Load 
and CD4 Count
The relationship between CD38 expression and viral load was positive (r=0.31, p<0.001). The 
percentage of activated CCR5+ expressing CD4 T cells was negatively associated with CD4 
count (r=-0.43, p<0.001) and positively related with viral load (r=0.31, p<0.001). CCR5 
expression was positively correlated to viral load (r=0.27, p<0.001) although the correlations 
were found statistically significant, they were weak. We did not find a significant correlation 
between coreceptor expressions and CD4 count.
4.7.3. Correlation of Coreceptor Expression, Immune Activation and T Cell Subset 
Distribution
The percentage of naïve CD4 T cells was positively associated with CD4 count (r=0.60, 
p<0.001) and negatively correlated with viral load (r=-0.42, p<0.001). The percentage of 
naïve CD4 T cells was also found negatively associated with antigen-experienced CD4 T cells
(r=-0.80, p<0.001)
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The percentage of antigen-experienced CD4 T cells was positively related to viral load 
(r=0.40, p<0.001) and negatively associated with CD4 count (r=-0.47, p<0.001).
The percentage of activated CCR5+ expressing CD4 T cells was positively related to 
percentage of antigen-experienced CD4 T cells (r=0.40, p<0.001) and negatively associated 
with percentage of naïve CD4 T cells (r=-0.30, p<0.001).
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CHAPTER 5:  DISCUSSION
CCR5 and CXCR4 are the major HIV coreceptors, critical for viral entry into host cells (Feng 
et al., 1996; Wu, 2009). They are differentially expressed by CD4 T cell subsets, and their 
relative expression has been associated with disease pathogenesis (Bleul et al., 1997; Lee et 
al., 2008). Immune activation, particularly T cell activation, is critical for productive HIV 
infection (Siliciano and Siliciano, 2000). Immune activation is now also recognised as a major 
driving force in AIDS pathogenesis (Hazenberg et al., 2003; Biancotto et al., 2008). Immune 
activation also directly impacts on T cell coreceptor expression (Shang H et al., 2005). TB 
and HIV coincide in Sub-Saharan Africa, and as both diseases are marked by immune 
activation and changes in T cell homeostasis, it is important to assess the impact of one 
disease on the other. ARV therapy is a potent suppressor of HIV-1 replication, and also of 
generalised immune activation, related to removal of antigenemia. An assessment of the role 
of ARV in regulation of coreceptor expression, immune activation (CD38) and CD4 T cell 
subset distribution, as well as the impact of HIV/TB disease, has been investigated in this 
study.
5.1. HIV Infected and HIV/TB Coinfected Patients without ARV
Before initiation of ARV treatment, HIV/TB coinfected patients displayed increased levels of 
CCR5 expression (p<0.05), CD38 expression (p<0.05), percentage of effector memory CD4 T 
cells (p<0.05) and percentage of total memory CD4 T cells when compared to HIV infected 
patients and healthy controls. There was also a significant decrease of naïve CD4 T cells in 
both the HIV and HIV/TB subgroup when compared to healthy controls (p<0.0001). 
The level of coreceptor expression per cell (as determined by MFI) and the percentage of cells 
expressing a particular coreceptor were not necessarily comparable. For example, the 
increased levels of CCR5 expression per cell in all groups (TB, HIV and TB/HIV) were 
accompanied by a decreased percentage CCR5 positive cell. This trend was not observed in 
the expression of CD38 (Figure 4.3 and Table 4.3), where increased marker expression was 
accompanied by increased percentage positive cells. These findings would appear to indicate 
the CCR5-expressing cells are preferentially lost from the peripheral blood at the same time 
that coreceptor expression is increased, probably related to increased activation.
To our knowledge, this is the first South African study to show an upregulated CCR5 
expression and immune activation status of CD4 T cells and an elevated percentage of 
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antigen-experienced CD4 T cells in HIV/TB coinfected patients. 
These results are similar to those previously reported by Juffermans et al. (2001) and Wolday 
et al. (2005) when examining expression of CCR5 and CXCR4 on CD4 T cells during active 
TB in HIV/TB coinfection. Our findings, however, contrast with those of Shalekoff et al. 
(2001) and Hanna et al. (2005), who could not demonstrate elevated CCR5 expression on 
CD4 T cells in HIV/TB infection. Distinct methodologies and differences in study 
populations may explain the contrast in findings. The two studies mentioned above have been 
performed using whole blood, which is different from this study performed on PBMCs 
isolated from fresh blood.
Infection with Mycobacterium tuberculosis in immunocompetent individuals does not usually 
lead to active disease. The immune response mounted to TB infection is usually efficient in 
containing bacteria. Therefore, in most cases, TB infection leads to an asymptomatic infection 
known as a clinically latent infection. During such a latent infection, M. tuberculosis is in a 
dormant non-replicating state, located primarily within macrophages contained within a 
granuloma in infected individual organs. However, in certain cases, due to the lack of an 
appropriate immune response, some patients may acquire active TB. In case of 
immunodeficiency (such as HIV infection) reactivation of latent infection may occur (Murphy 
et al., 2008; Flynn and Chan, 2001). 
MHC class II molecules are able to capture peptides from pathogens that have entered the 
vesicular system of macrophages. Thus TB infection is characterised by an antigen specific 
CD4 T cell response. The effector CD4 T cell subset primarily involved in combating TB 
infection is the TH1 subset, which can release cytokines (particularly interferon-) that activate 
macrophages to allow them to destroy pathogens (Murphy et al., 2008). Therefore, during 
active tuberculosis, infected macrophages induce stimulation of TH1 cells to produce pro-
inflammatory cytokines, which in turn will activate macrophages, but will also lead to 
increased CCR5 expression on CD4 T cells (Murphy et al., 2008; Stenger and Modlin, 1999; 
Boom et al., 2003; Schluger and Rom, 1998; Almeida et al., 2009). Consequently, during 
HIV/TB disease there are more activated CD4 T cells available because of the amplification 
of immune activation generated by the two infections (Wolday et al., 2005): one from HIV 
infection itself (antigenic stimulation) and another one produced through TH1 stimulation in 
active tuberculosis. 
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Active TB in HIV infection may create a microenvironment enhancing the productive 
infection of T cells by HIV (Bentwich et al., 1995; Valerie Garrait, 1997; Fraziano et al.,
1999; Bentwich et al., 2000; Djoba et al., 2007). This is also in line with Morris et al. (2003) 
who have demonstrated that R5 viral variants were preferentially recovered from patients with 
active TB. This can be related to the increased CCR5 expression on CD4 T cells and activated 
CCR5 expressing T cells found during HIV/TB disease (Figure 4.1 and Table 4.3).
Furthermore, this observation is confirmed by a positive correlation found between CCR5 
expression and viral load in this study (r=0.27, p<0.001).
There is a strong mutual interaction between HIV and TB infection as previously reported by 
Toossi (2003), who demonstrated continuous cellular activation and irregularities in cytokine 
and chemokine circuits that are permissive of viral replication. Interaction and interplay 
between HIV and TB infection was highlighted several years ago in an epidemiological study 
by Badri et al. (2001) in South Africa when assessing the impact of TB on HIV-1 disease 
progression in an area with high TB prevalence among HIV infected adults in Cape Town. 
Our findings support the concept that increased prolonged immune activation induced by 
HIV/TB disease may lead to increased HIV replication and enhance HIV disease progression 
(Corbett et al., 2003; Badri et al., 2001; Wood et al., 2000). Although the occurrence of HIV 
and TB infection simultaneously in a single host leads to increased immune activation and 
CCR5 expression, this finding is coupled with the observation that the percentage of CCR5 
expressing CD4 T cells is reduced. The activation of this subset of T cells is probably 
associated with increased apoptosis due to upregulation of Fas and FasL. We did not assess 
these markers or the levels of apoptosis in our study, but similar findings have been reported 
by others (Gougeon, 2005; Cannavo et al., 2001; Paiardini et al., 2004).
A limitation of this study is that we had insufficient data on the occurrence and impact of 
other opportunistic coinfections, such as Hepatitis C virus (Tan et al., 2006) in our study 
groups. As a result we could not determine their impact on immune activation status and their 
interaction with HIV infection and how this relates to the impact of TB coinfection. Several 
groups have demonstrated that helminthic infections increase the susceptibility to active TB in 
HIV dually infected patients (Borkow and Bentwich, 2004; Beyers et al., 1998; Elias et al.,
2007; Boraschi et al., 2008; Alvar et al., 2008). However, TB may be the most common 
opportunistic infection in the Western Cape area (Yach, 1988; Mehtar, 2008) that drives a 
CD4 T cell-mediated immune response (Boom et al., 2003). 
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Positive correlation was found in this study between CCR5 and CD38 expression, and 
CXCR4 and CD38 expression (Spearman coefficient of correlation: r=0.59, p<0.001 and 
r=0.55, p<0.001 respectively) (Figure 4.24). Ostrowski et al. (1998) previously reported a 
similar positive relationship when evaluating the levels of CCR5 and CXCR4 expression in 
HIV infected patients. This finding is also in accordance with Shang Hong et al. (2005), who 
demonstrated a correlation of coreceptor expression and immune activation of CD4 T cells in 
HIV/AIDS patients of China, although this study did not find a significant correlation 
between CXCR4 expression and immune activation markers. These findings appear to 
indicate that the upregulation of coreceptor expression is directly associated with increased 
expression of immune activation-associated markers. This seems feasible – as control of 
receptor expression is regulated by transcription factors, which in turn are primed in a 
generalized immune activation state (Lee et al., 2000; Moriuchi et al., 1997; Camargo et al.,
2009).
The median viral load in the untreated HIV/TB coinfected subgroup was 3.95 fold higher than 
in the HIV infected subgroup. Furthermore, we found the plasma viral load positively 
associated with CD38 expression (r=0.31, p<0.001) and the percentage of activated CCR5+ 
expressing CD4 T cells positively related to the viral load (r=0.31, p<0.001) for the HIV 
infected and HIV/TB coinfected subgroups. This is consistent with Cohen Stuart et al. (2000) 
who found in subjects without anti-HIV treatment, that plasma HIV-1 RNA level correlated 
with expression of CD38 in CD4+ and CD8+ T cells. Increased immune activation provides 
additional target cells for increased HIV replication, since HIV is known to replicate most 
efficiently in activated CD4 T cells (Cullen and Greene, 1989; Wolday et al., 2005; Sodora 
and Silvestri, 2008).
In this study, comparison of coreceptor expression, activation marker and CD4 T cell 
distribution in the HIV subgroup and the HIV/TB coinfected subgroup in patients with CD4 
counts above or below a cut-off of 200 cells/µl revealed consistent comparable trends. In both 
patients with CD4 < 200 cells/µl, as well as CD4 >200 cells/µl, CCR5 and CD38 expression 
were increased in the HIV/TB subgroup when compared to the HIV only subgroup (Figure 
4.13). Hence level of immunosuppression as indicated by CD4 count drop is not associated 
with the increased CCR5 and CD38 expression as demonstrated in this study. The 
overexpression of HIV coreceptors and the enhanced immune activation marker CD38 
observed in the HIV/TB subgroup is rather related to TB as an opportunistic infection and to 
generalized immune activation. 
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Although we did not collect data on clinical symptoms of patients and their date of HIV 
infection as required by the CDC classification system for HIV/AIDS patients (CDC, 1992), 
the level of severe immunosuppression usually associated with the late stage of disease seems 
clearly not to be the cause of higher CCR5 and CD38 expression found in the HIV/TB 
subgroup and the HIV subgroup when compared to healthy controls, but rather the increased 
immune activation found in HIV disease.
Chronic immune activation has been broadly reported as playing a prominent role in AIDS 
pathogenesis in recent years. HIV-infected patients display increased expression of a range of 
markers of activation (Forsman and Weiss, 2008; Boasso and Shearer, 2007). Originally, the 
common cause of T cell immune activation in HIV infection was focused on antigenic 
stimulation by the virus, and its induction of an adaptive immune response. The inability to 
clear the virus in untreated individuals leads to persistent or chronic immune responsiveness. 
There are, however, other causes or drivers of immune activation to be considered during the 
course of HIV infection. These include production of HIV proteins, reactivation of other 
viruses (e.g. cytomegalovirus), bacterial translocation and opportunistic coinfections e.g. 
active TB (Brenchley et al., 2006; Appay and Sauce, 2008). The findings of this study 
suggested active TB as a potent cause of increased immune activation status. However, we 
did not investigate TB infection status of healthy controls or infected people without over TB 
disease in this study to evaluate if this may also influence HIV disease progression.
In this study, CD4 counts in TB-infected individuals were found lower than the healthy 
individuals (Table 4.1). This may suggest a loss of CD4 cells in TB infection. Activated T 
cells are predisposed to apoptosis or programmed cell death. It is plausible that elevated 
susceptibility of MTB-responsive T cells to undergo apoptosis may contribute to the low T 
cells responses found in individuals with active MTB infection (Hirsch et al., 1999; Aleman 
et al., 2002). In patients with advanced pulmonary TB, more CD4+ T cells may be trapped in 
the infected lungs, reflecting a decreased circulating CD4+ T cells (Tsao et al., 2002; Uppal et 
al., 2004; Swaminathan et al., 2000; Deveci et al., 2006). 
T cell subset distribution in HIV/AIDS infection is disrupted (Galati et al., 2007). In the 
current study, elevated effector memory and total memory CD4 T cells were observed in the 
HIV/TB coinfected patients as compared to the HIV infected patients and healthy controls. A 
significant decrease of naïve CD4 T cells was also observed in both the HIV and HIV/TB 
subgroups compared to healthy controls. These findings confirm that HIV leads to disrupted T 
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cell distribution and homeostasis and that TB is a confounding factor in this disruption. These 
findings support the concept that there is a high turnover of T cells and a disruption in subset 
distribution (imbalance between production and death of T cells subset) in HIV infection 
(McCune et al., 2000; McCune, 2001; Mohri et al, 2001). Human TCM are involved in 
secondary responses and long term protection, whereas human TEM are memory cells that are 
characterized by rapid effector function and involved in immediate response (Lanzavecchia 
and Sallusto, 2005). TEM cells are short-lived and enriched for expression of CCR5 
compared to other memory CD4 T cells (Oswald-Richter et al., 2007; Blanpain et al., 2002). 
The normal balance of T cell distribution in peripheral blood of healthy individuals displays a 
picture of increased naïve CD4 T cells, elevated TCM CD4 cells and decreased TEM CD4 
cells (Murphy et al., 2008; Sallusto et al., 2004). The relative distribution of T cell subsets in 
the peripheral blood is not indicative of the situation in lymph nodes or other lymphoid organs 
or tissues.
Previous studies have shown HIV preferentially infects memory rather than naïve CD4 T cells 
in vivo (Douek et al., 2002; El-Far et al., 2008). Chronic immune activation may drive the 
dynamics of T cell homeostasis in HIV infection (Ribeiro et al., 2002) and cause a disruption 
in T cell subset distribution (McCune, 2001; Leng et al., 2001). This may lead to the 
expansion of TEM CD4 T cells at the expense of naïve and memory T cell pools. This 
imbalance will affect the immune system’s capacity to generate T cell mediated responses to 
antigens, e.g. progressive CD4 TCM cell decline resulting in CD4 TEM insufficiency (Picker, 
2006; Okoye A, 2007; Sodora and Silvestri, 2008). The decrease in percentage of naïve CD4 
T cells found in this study has been similarly described in previous reports suggesting the 
concept that naïve T cell depletion is one of the hallmarks of HIV infection (Di Mascio et al.,
2006; Hazemberg et al., 2000; Hellerstein et al., 2003).
In this study, we also found increased CD4 T cell memory positively associated with viral 
load, and negatively correlated with naïve CD4 T cells and CD4 count. This finding is in 
accordance with the concept of AIDS as a disease characterized by a prematurely ageing 
immune system (enhanced immune senescence). Through a process of chronic immune 
activation, HIV infection leads to an acceleration of the adaptive immune system ageing 
process, resulting in early disintegration of T cells (Sodora and Silvestri, 2008; Appay and 
Rowland-Jones, 2002).
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5.2. HIV Infected and HIV/TB Coinfected Patients after more than 6 months of
ARV
ARV therapy is an effective treatment strategy that leads to reduced viral load and increased 
CD4 count. In this study, the untreated HIV subgroup displayed a median CD4 count of 
173.5 ± 135.1 and a median viral load of 18 000 (4.3 log10 copies/ml). The median CD4 
absolute count and viral load in the HIV on ARV subgroup were 235.5 ± 162.2 and LDL 
(< 357 copies/ml), respectively. This finding is comparable to the recent report made by 
Hammond and Harry (2008) who suggested that ARV can be used effectively within the 
continent of Africa.
The results from the current study indicated a decline in immune activation status and 
expression of HIV coreceptors after ≥ 6 months of ARV and normalization of CD4 T cell 
subset distribution in HIV infection, but not HIV/TB disease.
CXCR4 expression (both percentage positive CD4+ T cells and MFI) in the HIV on ARV 
subgroup tends to increase (normalize) compared to untreated HIV infected patients (Figure 
4.12 and Figure 4.16). Redistribution of CD4 T cells after ARV treatment may explain this 
increase in CXCR4 expression (Smith et al., 2002; Pierdominici et al., 2002), as it may be 
related to the increase of percentage of naïve CD4 T cell, typically found to express more 
CXCR4+ (Table 4.4).
CCR5 and the immune activation marker CD38 display the same trend i.e. decreased 
expression after initiation of ARV, which is in accordance with the positive correlation found 
between these two parameters in this study. CCR5 expression decline may be considered as 
the consequence of decreased immune activation status as previously demonstrated by several 
groups (Giovannetti et al., 2001; Zhang et al, 2006; Smith et al., 2002). Interestingly those 
authors also found that this phenomenon does not occur with regard to CXCR4 expression. 
The relative importance of CD4+ T cell subset redistribution and/or immune activation in 
explaining the increased CXCR4 expression still needs to be addressed in further longitudinal 
studies. 
The change of CCR5 and CD38 expression in this study is not statistically significant 
(p>0.05) in treated compared to untreated patients. We speculate that this could be a result of 
the limited sample size and difference in standard deviation of means in our study group. To 
better understand and confirm the change in expression of CD4 T cells surface markers after 
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initiation of ARV, we suggest a larger longitudinal study. 
Interestingly, similar trends to those in the current study have recently been reported by Briz 
et al. (2008) when longitudinally examining HIV infected patients on ARV. They found that 
the long-term suppression of plasma HIV-RNA did not significantly influence CCR5 
expression on T lymphocytes. However, they did not find a difference of CCR5 level 
expression and percentage of naive CD4 T cells in HIV infected patients and healthy controls, 
which is in contrast with the findings of the present study. Zhang Zi-ning et al. (2006) have 
also found in a longitudinal study, that the decreased activation of CD4+ CCR5+ T cells was 
not significant after 6 months HAART compared to the level after 3 months of therapy.
Despite the suppression of plasma viral load to undetectable limit after ≥ 6 months of ARV, a 
reduced percentage of activated CD4 T cells expressing CCR5+ (Table 4.3) and decreased 
CCR5 coreceptor expression (Figure 4.15), ARV surprisingly still did not induce changes 
equivalent to levels observed in healthy controls. Previous studies have demonstrated the 
identical phenomenon (Smith et al., 2002; Al-Harthi et al., 2004; Benito et al., 2005; Mohri 
H, 2001; Cohen Stuart et al., 2000; Almeida et al., 2007; Aiuti and Mezzaroma, 2006; Valdez 
et al., 2002). This indicates that there is a loss of CCR5 expressing CD4 T cells that is never 
fully restored and also that immune activation continues despite an undetectable viral load. 
The gastro-intestinal tract damage model implies continued leakage of bacterial components 
from the blood and chronic innate immune stimulation. This model suggests that activation 
would continue even when viral load is under control (Dandekar, 2007; Brenchley and Douek, 
2008). Brenchley et al. (2006) have demonstrated that microbial translocation plays a central 
role causing HIV-related immune activation throughout the chronic phase of disease. They 
showed that increased LPS, used as an indicator of microbial translocation, correlated with 
elevated immune activation. Interestingly, they also found that HAART did not reduce 
microbial translocation completely. In this study, we did not look at LPS plasma levels in 
HIV infection to assess the effect of HAART on this parameter, however future studies should 
include such a component. TB-IRIS was not investigated in the HIV/TB group on ARVs to 
see if this may be associated with increased activation. However, the increased activation has 
been associated with active TB in this study even in the context of HIV/TB disease without 
ARV treatment.
In line with previous observations, this finding may possibly be due to the persistence of HIV 
antigens from the reservoir (i.e. virus from the latent pool) (Pierson et al., 2000; Belmonte et 
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al., 2003; Delobel et al., 2006), supplying a consistent antigen stimulation that may explain 
why T cell activation fails to revert to the levels found in healthy individuals (Cohen Stuart et 
al., 2000; Benito et al., 2005; Anthony et al., 2003). This may render eradication of HIV 
replication almost impossible being given that the latently infected cells form a drug-
insensitive reservoir that importantly contributes to the life-long persistence of HIV despite 
effective ARV therapy (Williams and Greene, 2007; Shen and Siliciano, 2008).
Pierson et al. (2000) have demonstrated that several lines of evidence suggest that new cells 
may become infected in patients on HAART whose plasma viral loads are below the limit of 
detection of current assays. Grossman et al. (2006) also suggested that the frequent activation 
of the spared cells in the lymph nodes during the chronic phase of HIV infection may 
facilitate continued viral replication. This may raise another question of what is a better or 
more suitable indicator to be used for monitoring ARV response, given this discordance 
between viral suppression and immune activation in patients on ARV treatment. Interestingly, 
previous studies have demonstrated for example that SIV-infected Sooty Mangabeys and 
African Green Monkeys which do not develop immunodeficiency, display reduced T cell 
activation despite high level of viremia (Appay and Sauce, 2008; Silvestri et al., 2003; 
Chakrabarti, 2004). Additional monitoring of ARV responses using immune activation 
biomarkers added to the classic indicators currently used may help to better assess the 
outcome of ARV.
In this study, we did not assess the lymphoid tissue for a possible relationship between cells 
infected from the reservoir, immune activation and surface markers during HAART. Further 
studies on the role of latent HIV and resting CD4 T cells from lymphoid tissue during 
HAART are needed, however such studies are difficult due to the invasive nature of lymph 
node biopsy or aspiration.
In this study, the percentage of naïve CD4 T cells was positively associated with CD4 count 
and negatively correlated to viral load in all subgroups. Furthermore restoration of naïve T 
cells in patients on ARV was reflected in the CD4 count. A significant increase of naïve CD4 
T cells and decrease of antigen-experienced CD4 T cells in HIV treated patients, suggestive of 
a normalization of T cell distribution after initiation of ARV, has been demonstrated in this 
study. Previous studies have reported similar findings (Carcelain et al., 1999; Landay et al.,
2002; Di Mascio et al., 2006).
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The effect of ARV on immune activation status shown by a decrease of CD38 expression may 
lead to viral suppression and logically explain the normalization of CD4 T cell distribution, 
which was disrupted before treatment. Normalization of CD4 T cell distribution after ARV 
treatment was moreover confirmed by the increased percentage of naïve CD4 T cells found in 
the HIV ARV responder subgroup when compared to ARV non-responder subgroup and 
elevated percentage of antigen-experienced cells in HIV ARV non-responder when compared 
to HIV ARV responder subgroup.
Surprisingly, increased naïve CD4 T cells after ARV in HIV infection was still far from the 
normal percentage of naïve CD4 T cells found in healthy controls (p<0.005). This is in 
accordance with previous reports (Al-Harthi et al., 2004; Anthony et al., 2003) which 
demonstrated that T cell turnover is decreased after 12 months of ARV, but does not 
normalize despite suppression of viral load. This finding supports the hypothesis that 
increased turnover in HIV infection is mainly associated with ongoing immune system 
activation and not with T cell homeostasis (Anthony et al., 2003; Benito et al., 2005; Aiuti et 
al., 2006; Blankson et al., 2002).
In this study, we assessed the effect of ARV on CD4 T cells from PBMC. This process may 
limit the interpretation of our findings as previous studies have shown that blood is not 
representative of lymphoid tissues that are critical highly active immunological sites (Fleury 
and Pantaleo, 1999; Guadalupe et al., 2003). Peripheral blood may not always give a correct 
reflection of what is occurring within the body. The number of CD4 T cells circulating in the 
blood where only 15% may be memory cells, may not reflect what is present in lymph nodes 
(Levy, 2007). Approximately 98% of total CD4 T cell pool in the body is found in secondary 
lymphoid tissue. However peripheral blood is the most commonly studied immune 
compartment because of its accessibility (Schacker, 2008).
The effect of ARV on immune activation-associated surface marker expression and 
coreceptor expression has been reported by several groups since the introduction of ARV for 
the treatment of HIV infection (Evans et al., 1998; Lempicki et al, 2000; Hunt et al., 2003; 
Hazenberg et al., 2000). There has however been minimal reporting in the context of HIV/TB 
coinfection. To our knowledge, this study is the first to assess the effect of ARV on 
coreceptor expression, in vivo immune activation-associated surface marker expression and 
CD4 T cell subset distribution in HIV/TB coinfection. The present study has shown that there 
is an increased immune activation of CD4 T cells, which leads to an over expression of 
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coreceptors and consistent alteration in turnover of CD4 T cells leading to changes in subset 
distribution in HIV/TB disease.
In HIV/TB coinfected patients after ≥ 6 months of ARV there is a partially reduced immune 
activation marker and HIV coreceptor expression. Naïve CD4 T cells were found not to be 
significantly increased and antigen-experienced CD4 T cells as well, were not decreased 
compared to untreated HIV/TB coinfected patients. This feature is comparable to what is 
found in the HIV ARV non responder subgroup (Figure 4.23) as shown above in this study.
This observation may indicate a clear negative influence of HIV/TB disease on ARV 
treatment outcome and explain the reason why treatment of HIV/TB coinfected individuals 
does not seem to display expected changes as observed in HIV infection alone. This is most 
likely due to the exacerbated immune activation status found in active TB. This finding must 
be correlated with clinical outcome to confirm our observation. However, failure of therapy or 
insufficient viral suppression may also possibly lead to such negative outcome. On the other 
hand, we did not collect information on patient adherence to ARV and/or TB treatment, as 
well as clinical outcome in this study, especially possible drug resistance, which does not 
allow us to discuss the outcome of treatment with ARV in the context of TB in depth. Due to 
the limited sample collection, we were not able to study the effect of concurrent ARV and TB 
treatment. However two-thirds of our HIV/TB coinfected patients (Table 4.2) were on TB 
treatment. Further longitudinal studies are needed to investigate how this may influence the 
treatment outcome.
An inherent weakness of this study (and any cross-sectional immune-based study) is the fact 
that we did not repeat assessment of HIV coreceptor and immune activation marker 
expression at baseline and different point times during the ARV treatment to see if the trends 
were consistent. Nevertheless, previous prospective studies on HIV and HIV/TB coinfected 
patients as discussed above have been reported with similar observations to our findings. 
Increased immune activation is a feature of HIV/TB disease determining to what extent HIV 
coreceptor over expression, as well as CD4 T cell turnover, has an influence on the negative 
outcome of ARV treatment (as shown in this study). However, its aetiology is multifactorial 
(Appay and Sauce, 2008; Sodora and Silvestri, 2008). Antigen stimulation itself is not 
sufficient as the cause of increased immune activation in HIV/TB disease, because the 
suppression of plasma viral load to undetectable limit after ≥ 6 months of ARV found in the 
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HIV/TB on ARV subgroup in this study (Table 4.1) was not automatically followed by the 
expected change in immune activation status, coreceptor expression and CD4 T cell 
distribution after ARV treatment. However, in the HIV on ARV subgroup, a considerable 
change could be observed after ARV treatment. 
Because of limited participant numbers, we did not investigate the concomitant effect of TB 
treatment and ARV treatment. Further longitudinal studies with large cohorts of HIV/TB 
coinfected patients on both treatments will help to elucidate the cause of negative ARV 
response. 
One could speculate on the role of microbial translocation in HIV infection during ARV 
treatment, as Brenchley et al. (2006) found LPS not reduced after treatment, which is 
comparable to the finding of this study when assessing the effect of ARV on immune 
activation marker, coreceptor expression and CD4 T cell subset distribution in HIV/TB 
disease. Alternatively, persistent TB antigen may also impact on continued immune 
activation. Perhaps HIV/TB disease leads to an increased LPS plasma level, which would be 
partially reduced by ARV treatment. This may occur through damage to the lung in addition 
to the GIT.
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CHAPTER 6:  CONCLUSION
This study was performed to assess the role of ARV on regulation of coreceptors expression, 
immune activation status and CD4 T cell subset distribution in HIV infected and HIV/TB 
coinfected adult patients.
The findings of this study revealed: 
1. In the absence of ARV therapy, CD4 T cell immune activation is increased in HIV 
infection and further enhanced in HIV/TB infection and may consequently cause over 
expression of HIV coreceptors, as well as a high turnover of CD4 T cell subsets 
distribution; 
2. After more than 6 months of ARV treatment, a decrease of immune activation may lead 
to a decrease of CCR5 expression and normalization of CD4 T cell subset distribution 
in HIV infected patients, but not in HIV/TB coinfected patients.
Enhanced increase of immune activation status found in HIV/TB disease may explain the 
reason why treatment of TB coinfection seems not to display a change as expected and show a 
clear negative influence of HIV/TB disease on ARV treatment outcome. However, failure of 
therapy or insufficient viral suppression may possibly lead to such negative outcome.
Despite viral suppression after ARV treatment, the decrease of CD4 T cell immune activation 
and CCR5 expression, increase of percentage naïve CD4 T cells and decrease of antigen-
experienced CD4 T cells did not reach normal levels compared to healthy controls. This 
finding may indicate an ongoing T cell immune activation, which is partially reduced, and 
suggest further longitudinal studies to closely monitor immune activation during ARV 
treatment. It would be beneficial even in the classic routine monitoring of ARV treatment to 
include the assessment of CD4 T cell immune activation biomarker for a better evaluation of 
treatment outcome.
This study, which was a cross sectional analysis with limited sample collection, could not 
totally help our understanding on the interactions of other coinfections during ARV treatment, 
different factors involved in HIV immune activation during ARV treatment and effect of 
concomitant treatments (ARV and TB treatment). In addition, reports on clinical symptoms 
and adherence to ARV and TB treatment are required in future to confirm the findings of this 
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study. Hence, more studies are needed to extend the list of different factors besides the 
antigen stimulation that may lead to a persistent immune activation status during ARV 
treatment. 
These results suggest a different or modified approach to ARV treatment in HIV positive 
patients with TB disease. The current findings may point to the fact that the bottom line in 
management of HIV infection, as well as HIV/TB disease treatment should evaluate if such a 
reduction in immune activation is indeed followed by improved outcome. The goal of ARV 
therapy (or other therapies) should be to reduce as much as possible the increased immune 
activation status. Treatment that could contain the renewal of HIV replication from latent 
reservoirs in the lymphoid tissue and also suppress the effects of LPS (or other GIT stimuli) in 
plasma, consequently reducing immune activation status in HIV infection, as well HIV/TB 
disease should be highly beneficial.
This study has highlighted an association of TB disease with immune activation in HIV 
infection and its impact on ARV treatment. In future, successful ARV treatment of HIV 
infection and HIV/TB disease would suggest treatment, which efficiently reduces immune 
activation status.
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